

Frequency of Stages of Alzheimer-Related Lesions in Di

Neurobiology of Aging

18, 351-357

DOI: 10.1016/s0197-4580(97)00056-0

Citation Report

#	ARTICLE	IF	CITATIONS
1	Polyadenylation of nascent RNA during the embryogenesis of <i>Ilyanassa obsoleta</i> . <i>Experimental Cell Research</i> , 1975, 95, 263-268.	2.6	12
2	DNA Testing Detente?. <i>Science</i> , 1995, 268, 371-371.	12.6	0
3	Plaques and Tangles: Searching for Primary Events in a Forest of Data. <i>Neurobiology of Aging</i> , 1997, 18, 358-362.	3.1	20
4	The Biological Significance of Neuropathological Lesions in Alzheimer's Disease. <i>Neurobiology of Aging</i> , 1997, 18, 379-382.	3.1	2
5	Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories. <i>Neurobiology of Aging</i> , 1997, 18, 377-379.	3.1	35
6	The Natural History of Alzheimer Neurofibrillary Tangles and Amyloid Deposits. <i>Neurobiology of Aging</i> , 1997, 18, 386-387.	3.1	26
7	Alzheimer-type lesions in Huntington's disease. <i>Journal of Neural Transmission</i> , 1998, 105, 787-799.	2.8	44
8	Age Effects on Central Nervous System Activity Reflected in the Olfactory Event-Related Potential: Evidence for Decline in Middle Age. <i>Annals of the New York Academy of Sciences</i> , 1998, 855, 598-607.	3.8	19
9	Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. <i>Journal of Neural Transmission</i> , 1998, 105, 801-819.	2.8	180
10	The role of APOE polymorphisms in late-onset dementias. <i>Cellular and Molecular Life Sciences</i> , 1998, 54, 928-934.	5.4	78
11	Tau protein pathology in neurodegenerative diseases. <i>Trends in Neurosciences</i> , 1998, 21, 428-433.	8.6	652
12	Cognitive decline strongly correlates with cortical atrophy in Alzheimer's dementia. <i>Neurobiology of Aging</i> , 1998, 19, 371-377.	3.1	107
13	Rapid Assembly of Alzheimer-like Paired Helical Filaments from Microtubule-Associated Protein Tau Monitored by Fluorescence in Solution. <i>Biochemistry</i> , 1998, 37, 10223-10230.	2.5	378
14	Filamentous nerve cell inclusions in neurodegenerative diseases. <i>Current Opinion in Neurobiology</i> , 1998, 8, 619-632.	4.2	247
15	Tau Mutations Cause Frontotemporal Dementias. <i>Neuron</i> , 1998, 21, 955-958.	8.1	294
16	High Frequency of Apolipoprotein E ϵ 4 Allele in Young Individuals with Very Mild Alzheimer's Disease-Related Neurofibrillary Changes. <i>Experimental Neurology</i> , 1998, 153, 152-155.	4.1	118
17	A nucleated assembly mechanism of Alzheimer paired helical filaments. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 15712-15717.	7.1	328
18	Chapter 21 Neurofibrillary pathology of Alzheimer's disease and other tauopathies. <i>Progress in Brain Research</i> , 1998, 117, 287-306.	1.4	64

#	ARTICLE	IF	CITATIONS
20	Identification of Microglial Signal Transduction Pathways Mediating a Neurotoxic Response to Amyloidogenic Fragments of I ² -Amyloid and Prion Proteins. Journal of Neuroscience, 1999, 19, 928-939.	3.6	336
21	Inhibition of NF- κ B potentiates amyloid β -mediated neuronal apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9409-9414.	7.1	276
22	Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology, 1999, 53, 1391-1391.	1.1	186
23	Amyloid and lipids in the pathology of Alzheimer disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1999, 6, 136-145.	3.0	59
24	Remote Odor Memory in Alzheimer's Disease: Deficits as Measured by Familiarity. Journal of Adult Development, 1999, 6, 131-136.	1.4	23
25	GABA transporters (GAT-1) in Alzheimer's disease. Journal of Neural Transmission, 1999, 106, 1141-1149.	2.8	32
26	Anti-inflammatory substances – a new therapeutic option in Alzheimer's disease. Drug Discovery Today, 1999, 4, 275-282.	6.4	25
27	Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Annals of Neurology, 1999, 45, 358-368.	5.3	1,569
28	Alternatively spliced isoforms of FE65 serve as neuron-specific and non-neuronal markers. , 1999, 58, 632-640.		23
29	Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S14-S22.	3.2	313
30	Very Early Decline in Recognition Memory for Odors in Alzheimer's Disease. Aging, Neuropsychology, and Cognition, 1999, 6, 229-240.	1.3	16
31	A Test of Odor Fluency in Patients with Alzheimer's and Huntington's Disease. Journal of Clinical and Experimental Neuropsychology, 1999, 21, 341-351.	1.3	51
32	Emerging strategies for the treatment of Alzheimer's disease at the Millennium. Expert Opinion on Emerging Drugs, 1999, 4, 35-86.	1.1	1
33	Glutamate but not interleukin-6 influences the phosphorylation of tau in primary rat hippocampal neurons. Neuroscience Letters, 1999, 261, 33-36.	2.1	5
34	Memory and mental status correlates of modified Braak staging. Neurobiology of Aging, 1999, 20, 573-579.	3.1	231
35	Loss of Olfactory Function in Dementing Disease. Physiology and Behavior, 1999, 66, 177-182.	2.1	141
36	Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philosophical Transactions of the Royal Society B: Biological Sciences, 1999, 354, 1101-1118.	4.0	165
37	Sex-Dependent Cytoskeletal Changes of the Human Hypothalamus Develop Independently of Alzheimer's Disease. Experimental Neurology, 1999, 160, 186-193.	4.1	33

#	ARTICLE	IF	CITATIONS
38	Regional distribution of tau, β -amyloid and β -amyloid precursor protein in the Alzheimer's brain. <i>NeuroReport</i> , 1999, 10, 3785-3789.	1.2	25
39	Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β -Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPAR γ Agonists. <i>Journal of Neuroscience</i> , 2000, 20, 558-567.	3.6	558
40	Cerebral Hypoperfusion, Capillary Degeneration, and Development of Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2000, 14, S72-S81.	1.3	75
41	A Unifying Hypothesis of Alzheimer's Disease. IV. Causation and Sequence of Events. <i>Reviews in the Neurosciences</i> , 2000, 11, 213-328.	2.9	78
42	Sequence of A β -Protein Deposition in the Human Medial Temporal Lobe. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 733-748.	1.7	305
43	Broadly altered expression of the mRNA isoforms of FE65, a facilitator of beta amyloidogenesis, in Alzheimer cerebellum and other brain regions. , 2000, 60, 73-86.		26
44	Alzheimer's Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2000, 27, 1-8.	1.9	174
45	The evolution of Alzheimer's disease-related cytoskeletal pathology in the human raphe nuclei. <i>Neuropathology and Applied Neurobiology</i> , 2000, 26, 553-567.	3.2	108
46	Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). <i>Neurogenetics</i> , 2000, 2, 0193-0205.	1.4	30
47	Revisiting Alzheimer's Disease from a New Prospective: Can "Risk Factors" Play a Key Role?. <i>Journal of Alzheimer's Disease</i> , 2000, 2, 113-114.	2.6	2
48	Anti-inflammatory drugs: a hope for Alzheimer's disease?. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 671-683.	4.1	46
49	Alzheimer-Related β -Pathology in the Perforant Path Target Zone and in the Hippocampal Stratum Oriens and Radiatum Correlates with Onset and Degree of Dementia. <i>Experimental Neurology</i> , 2000, 163, 98-110.	4.1	148
50	Elevated A β ₂₄₂ in Skeletal Muscle of Alzheimer Disease Patients Suggests Peripheral Alterations of A β PP Metabolism. <i>American Journal of Pathology</i> , 2000, 156, 797-805.	3.8	153
51	Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. <i>Brain Research Reviews</i> , 2000, 34, 119-136.	9.0	264
52	Age-related progression of tau pathology in brains of baboons. <i>Neurobiology of Aging</i> , 2000, 21, 905-912.	3.1	73
53	Tau aggregation into fibrillar polymers: tauopathies. <i>FEBS Letters</i> , 2000, 476, 89-92.	2.8	77
54	Suicide and Alzheimer's pathology in the elderly: a case-control study. <i>Biological Psychiatry</i> , 2001, 49, 137-145.	1.3	104
55	Alzheimer's disease: a review concerning immune response and microischemia. <i>Medical Hypotheses</i> , 2001, 56, 124-127.	1.5	23

#	ARTICLE	IF	CITATIONS
56	Neuropathological epidemiology of cerebral aging: a study of two genetic polymorphisms. <i>Neurobiology of Aging</i> , 2001, 22, 227-235.	3.1	19
57	Tau, β -amyloid and β -amyloid precursor protein distribution in the entorhinal-hippocampal alvear and perforant pathways in the Alzheimer's brain. <i>Neuroscience Letters</i> , 2001, 303, 193-197.	2.1	17
58	The premotor region essential for rapid vertical eye movements shows early involvement in Alzheimer's disease-related cytoskeletal pathology. <i>Vision Research</i> , 2001, 41, 2149-2156.	1.4	40
59	Alzheimer's Disease, Neural Basis of. , 2001, , 425-430.		1
61	β -Amyloid Stimulation of Microglia and Monocytes Results in TNF α -Dependent Expression of Inducible Nitric Oxide Synthase and Neuronal Apoptosis. <i>Journal of Neuroscience</i> , 2001, 21, 1179-1188.	3.6	640
63	Blockade of Long-Term Potentiation by β -Amyloid Peptides in the CA1 Region of the Rat Hippocampus In Vivo. <i>Journal of Neurophysiology</i> , 2001, 85, 708-713.	1.8	140
64	Olfactory Function and Event-Related Potentials in Alzheimer's Disease. , 0, , 237-251.		0
66	Fibrillar amyloid- β affects neurofibrillary changes but only in neurons already involved in neurofibrillary degeneration. <i>Acta Neuropathologica</i> , 2001, 101, 585-590.	7.7	4
67	Cortical Lewy body pathology in the diagnosis of dementia. <i>Acta Neuropathologica</i> , 2001, 102, 355-363.	7.7	262
68	History of Depression as a Risk Factor for Dementia: An Updated Review. <i>Australian and New Zealand Journal of Psychiatry</i> , 2001, 35, 776-781.	2.3	451
69	Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2001, 17, 101-118.	2.3	449
70	Title is missing!. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2001, 249, 443-447.	1.5	2
71	Early involvement of the tegmentopontine reticular nucleus during the evolution of Alzheimer's disease-related cytoskeletal pathology. <i>Brain Research</i> , 2001, 908, 107-112.	2.2	20
72	Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease. <i>Archives of Neurology</i> , 2001, 58, 1395.	4.5	509
73	Declining brain activity in cognitively normal apolipoprotein E ϵ 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 3334-3339.	7.1	444
74	Alzheimer's disease: Its diagnosis and pathogenesis. <i>International Review of Neurobiology</i> , 2001, 48, 167-217.	2.0	17
75	Gender and age modify the association between APOE and AD-related neuropathology. <i>Neurology</i> , 2001, 56, 1696-1701.	1.1	95
76	Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. <i>Brain</i> , 2002, 125, 2332-2341.	7.6	115

#	ARTICLE	IF	CITATIONS
77	Where Does Parkinson Disease Pathology Begin in the Brain?. Journal of Neuropathology and Experimental Neurology, 2002, 61, 413-426.	1.7	640
78	Hippocampal volume as an index of Alzheimer neuropathology. Neurology, 2002, 58, 1476-1482.	1.1	308
79	Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain, 2002, 125, 1772-1781.	7.6	177
80	Dementia, asymmetry of temporal lobe structures, and Apolipoprotein E genotype: Relationships to cerebral atrophy and neuropsychological impairment. Journal of the International Neuropsychological Society, 2002, 8, 925-933.	1.8	40
81	Women at risk for AD show increased parietal activation during a fluency task. Neurology, 2002, 58, 1197-1202.	1.1	104
82	Chapter 43 Dementia and qEEG (Alzheimer's disease). Supplements To Clinical Neurophysiology, 2002, , 289-294.	2.1	12
83	Tau Conformational Changes Correspond to Impairments of Episodic Memory in Mild Cognitive Impairment and Alzheimer's Disease. Experimental Neurology, 2002, 177, 475-493.	4.1	167
84	Dementia, the fate of brain? Neuropathological point of view. Comptes Rendus - Biologies, 2002, 325, 655-664.	0.2	7
85	Olfactory impairment increases as a function of age in persons with Down syndrome. Neurobiology of Aging, 2002, 23, 65-73.	3.1	41
86	Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer's disease. Neurobiology of Aging, 2002, 23, 179-186.	3.1	30
87	Functional neuroimaging in psychiatry. International Congress Series, 2002, 1247, 651-661.	0.2	0
88	Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains. Neuroscience Letters, 2002, 320, 25-28.	2.1	26
89	Fisiopatología de la enfermedad de Alzheimer. EMC - Tratado De Medicina, 2002, 6, 1-11.	0.0	0
90	Localization of Neurofibrillary Tangles and Beta-Amyloid Plaques in the Brains of Living Patients With Alzheimer Disease. American Journal of Geriatric Psychiatry, 2002, 10, 24-35.	1.2	650
91	Immunoassay for Serum Glutamine Synthetase in Serum: Development, Reference Values, and Preliminary Study in Dementias. Clinical Chemistry, 2002, 48, 375-378.	3.2	13
93	The Brain of the Aging Baboon: A Nonhuman Primate Model for Neuronal and Glial Tau Pathology. , 2002, 31, 118-129.		7
94	Odor Memory in Alzheimer's Disease. , 2002, , 261-277.		2
95	Disturbed visual processing contributes to impaired reading in Alzheimer's disease. Neuropsychologia, 2002, 40, 902-909.	1.6	23

#	ARTICLE	IF	CITATIONS
96	Working memory and apolipoprotein E: What's the connection?. <i>Neuropsychologia</i> , 2002, 40, 2226-2233.	1.6	103
97	Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1627-1656.	13.7	126
98	Tau aggregation in the hippocampal formation: an ageing or a pathological process?. <i>Experimental Gerontology</i> , 2002, 37, 1291-1296.	2.8	88
99	Early inflammation and dementia: A 25-year follow-up of the Honolulu Asia aging study. <i>Annals of Neurology</i> , 2002, 52, 168-174.	5.3	655
100	Olfactory functional testing: sensitivity and specificity for Alzheimer's disease. <i>Drug Development Research</i> , 2002, 56, 123-131.	2.9	15
101	Role of GSK-3 β in Alzheimer's disease pathology. <i>Drug Development Research</i> , 2002, 56, 491-510.	2.9	77
102	Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. <i>Acta Neuropathologica</i> , 2002, 103, 370-376.	7.7	159
103	ERK activation and nuclear translocation in amyloid- β peptide- and iron-stressed neuronal cell cultures. <i>European Journal of Neuroscience</i> , 2002, 16, 44-54.	2.6	55
104	Tau Function and Dysfunction in Neurons. <i>Molecular Neurobiology</i> , 2002, 25, 213-232.	4.0	54
105	Lysosomes and brain aging in mammals. <i>Neurochemical Research</i> , 2003, 28, 1725-1734.	3.3	34
106	A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile. <i>Neuropsychology Review</i> , 2003, 13, 1-18.	4.9	124
107	Aggregation Analysis of the Microtubule Binding Domain in Tau Protein by Spectroscopic Methods. <i>Journal of Biochemistry</i> , 2003, 134, 91-99.	1.7	51
108	PET studies in dementia. <i>Annals of Nuclear Medicine</i> , 2003, 17, 79-89.	2.2	207
109	Neuropathological features of a case with schizophrenia and prion protein gene P102L mutation before onset of Gerstmann-Sträussler-Scheinker disease. <i>Acta Neuropathologica</i> , 2003, 106, 92-96.	7.7	6
110	Olfactory identification in elderly Greek people in relation to memory and attention measures. <i>Archives of Gerontology and Geriatrics</i> , 2003, 37, 119-130.	3.0	28
111	Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. <i>Experimental Neurology</i> , 2003, 182, 322-334.	4.1	110
112	Staging of brain pathology related to sporadic Parkinson's disease. <i>Neurobiology of Aging</i> , 2003, 24, 197-211.	3.1	8,567
113	A grading system of Alzheimer disease lesions in neocortical areas. <i>Neurobiology of Aging</i> , 2003, 24, 563-572.	3.1	50

#	ARTICLE	IF	CITATIONS
114	cAMP-specific phosphodiesterases expression in Alzheimer's disease brains. International Congress Series, 2003, 1251, 127-138.	0.2	9
115	The Role of Insulin Resistance in the Pathogenesis of Alzheimer's Disease. CNS Drugs, 2003, 17, 27-45.	5.9	366
116	Alzheimer's disease skin fibroblasts selectively express a bradykinin signaling pathway mediating tau protein Ser phosphorylation. FASEB Journal, 2003, 17, 2319-2321.	0.5	21
117	Neurofibrillary Tangles, Amyloid, and Memory in Aging and Mild Cognitive Impairment. Archives of Neurology, 2003, 60, 729.	4.5	491
118	White Matter Structural Integrity in Healthy Aging Adults and Patients With Alzheimer Disease. Archives of Neurology, 2003, 60, 393.	4.5	376
119	Neuropathology of Cognitively Normal Elderly. Journal of Neuropathology and Experimental Neurology, 2003, 62, 1087-1095.	1.7	541
122	Neurons treated with cyclo-oxygenase-1 inhibitors are resistant to amyloid- β 1-42. NeuroReport, 2003, 14, 2099-2103.	1.2	24
123	Left hippocampal volume loss in Alzheimer's disease is reflected in performance on odor identification: A structural MRI study. Journal of the International Neuropsychological Society, 2003, 9, 459-471.	1.8	112
124	Aging, Preclinical Alzheimer Disease, and Early Detection. Alzheimer Disease and Associated Disorders, 2003, 17, S60-S62.	1.3	3
125	Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia. Neurology, 2003, 61, 1673-1679.	1.1	65
126	In vivo cerebrovascular actions of amyloid β -peptides and the protective effect of conjugated estrogens. Journal of Alzheimer's Disease, 2003, 5, 275-286.	2.6	35
127	PS2APP Transgenic Mice, Coexpressing hPS2mut and hAPPswe, Show Age-Related Cognitive Deficits Associated with Discrete Brain Amyloid Deposition and Inflammation. Journal of Neuroscience, 2003, 23, 8989-9003.	3.6	178
128	Effects of the ApoE ϵ 4 allele on olfactory function in Down Syndrome. Journal of Alzheimer's Disease, 2004, 6, 397-402.	2.6	13
129	Identification of Cathepsin B as a Mediator of Neuronal Death Induced by $A\beta$ -activated Microglial Cells Using a Functional Genomics Approach. Journal of Biological Chemistry, 2004, 279, 5565-5572.	3.4	117
130	The Effect of the ApoE ϵ 4 Allele on Recognition Memory for Olfactory and Visual Stimuli in Patients with Pathologically Confirmed Alzheimer's Disease, Probable Alzheimer's Disease, and Healthy Elderly Controls. Journal of Clinical and Experimental Neuropsychology, 2004, 26, 779-794.	1.3	65
131	Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 284-289.	7.1	907
132	Altered Amyloid- β Metabolism and Deposition in Genomic-based β -Secretase Transgenic Mice. Journal of Biological Chemistry, 2004, 279, 52535-52542.	3.4	35
133	Differences in olfactory and visual memory in patients with pathologically confirmed Alzheimer's disease and the Lewy body variant of Alzheimer's disease. Journal of the International Neuropsychological Society, 2004, 10, 835-842.	1.8	33

#	ARTICLE	IF	CITATIONS
134	Differential Vulnerability of Anterior White Matter in Nondemented Aging with Minimal Acceleration in Dementia of the Alzheimer Type: Evidence from Diffusion Tensor Imaging. <i>Cerebral Cortex</i> , 2004, 14, 410-423.	2.9	561
135	Alzheimer's Disease: Neuropathologic Findings and Recent Advances in Imaging. <i>American Journal of Roentgenology</i> , 2004, 182, 3-13.	2.2	55
136	Argyrophilic grain disease: A late-onset dementia with distinctive features among tauopathies. <i>Neuropathology</i> , 2004, 24, 269-283.	1.2	121
137	Neuroprotective effect of cannabidiol, a non-psychoactive component from <i>Cannabis sativa</i> , on beta-amyloid-induced toxicity in PC12 cells. <i>Journal of Neurochemistry</i> , 2004, 89, 134-141.	3.9	289
138	The New "Silent" Epidemic. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1212-1213.	2.6	4
139	Effect of Vascular Lesions on Cognition in Alzheimer's Disease: A Community-Based Study. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1442-1448.	2.6	107
140	Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. <i>Lancet Neurology</i> , The, 2004, 3, 184-190.	10.2	760
141	Differences between recognition memory and remote memory for olfactory and visual stimuli in nondemented elderly individuals genetically at risk for Alzheimer's disease. <i>Experimental Gerontology</i> , 2004, 39, 433-441.	2.8	32
142	"Silent stroke": An oxymoron meaning "dementia". <i>Seminars in Cerebrovascular Diseases and Stroke</i> , 2004, 4, 97-101.	0.1	7
143	The Biphasic Relationship between Regional Brain Senile Plaque and Neurofibrillary Tangle Distributions: Modification by Age, Sex, and <i>APOE</i> Polymorphism. <i>Annals of the New York Academy of Sciences</i> , 2004, 1019, 24-28.	3.8	193
144	Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1540-1543.	6.4	4
145	Pro-apoptotic signaling in neuronal cells following iron and amyloid beta peptide neurotoxicity. <i>Journal of Neurochemistry</i> , 2004, 86, 114-125.	3.9	47
147	Neuropathology of Alzheimer's Disease, as Seen in Fixed Tissues. , 2004, , 1-15.		0
148	Facts, myths, and controversies in vascular dementia. <i>Journal of the Neurological Sciences</i> , 2004, 226, 49-52.	0.6	80
149	Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. <i>Experimental Neurology</i> , 2004, 190, 192-203.	4.1	358
150	Looking for the link between plaques and tangles. <i>Neurobiology of Aging</i> , 2004, 25, 735-739.	3.1	46
151	Alzheimer's disease: intraneuronal alterations precede insoluble amyloid- β formation. <i>Neurobiology of Aging</i> , 2004, 25, 713-718.	3.1	70
152	So what if tangles precede plaques?. <i>Neurobiology of Aging</i> , 2004, 25, 721-723.	3.1	31

#	ARTICLE	IF	CITATIONS
153	Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, 5-18.	3.1	834
154	Poor and protracted myelination as a contributory factor to neurodegenerative disorders. <i>Neurobiology of Aging</i> , 2004, 25, 19-23.	3.1	137
155	Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, 843-851.	3.1	348
156	Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. <i>Neurobiology of Aging</i> , 2004, 25, 697-711.	3.1	219
157	A polymorphism of the interleukin-1 beta gene at position +3953 influences progression and neuro-pathological hallmarks of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, 1017-1022.	3.1	39
158	Amyloid beta peptide directly inhibits PKC activation. <i>Molecular and Cellular Neurosciences</i> , 2004, 26, 222-231.	2.2	60
159	The role of GSK-3beta in the formation of neurofibrillary tangles. <i>Psychogeriatrics</i> , 2004, 4, S51-S56.	1.2	1
160	A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. <i>Neurology</i> , 2004, 63, 1155-1162.	1.1	298
161	Proteomic Analysis of Human Ventricular Cerebrospinal Fluid from Neurologically Normal, Elderly Subjects Using Two-Dimensional LC-MS/MS. <i>Journal of Proteome Research</i> , 2004, 3, 97-103.	3.7	69
162	High prevalence of thorn-shaped astrocytes in the aged human medial temporal lobe. <i>Neurobiology of Aging</i> , 2004, 25, 397-405.	3.1	81
163	Pathological Aging of the Brain. <i>Topics in Magnetic Resonance Imaging</i> , 2004, 15, 369-389.	1.2	60
164	Microglia kill amyloid- β 1-42 damaged neurons by a CD14-dependent process. <i>NeuroReport</i> , 2004, 15, 1427-1430.	1.2	37
165	Memory complaints in a community sample aged 60-64 years: associations with cognitive functioning, psychiatric symptoms, medical conditions, APOE genotype, hippocampus and amygdala volumes, and white-matter hyperintensities. <i>Psychological Medicine</i> , 2004, 34, 1495-1506.	4.5	172
166	Stress and dementia. <i>Handbook of Behavioral Neuroscience</i> , 2005, , 357-370.	0.0	2
167	Early-Stage and Preclinical Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 163-165.	1.3	147
168	The Cure of One of the Most Frequent Types of Dementia: A Historical Parallel. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 156-158.	1.3	12
169	Dementia Update 2005. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 100-117.	1.3	58
170	2005 Potamkin Prize Awarded for Research in Early Detection of Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 162.	1.3	0

#	ARTICLE	IF	CITATIONS
171	Independent accumulations of tau and amyloid β -protein in the human entorhinal cortex. <i>Neurology</i> , 2005, 64, 687-692.	1.1	25
175	Normal rates of cognitive change in successful aging: The Freedom House Study. <i>Journal of the International Neuropsychological Society</i> , 2005, 11, 899-909.	1.8	94
176	Progress in Clinical Neurosciences: Cognitive Markers of Progression in Alzheimer's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 140-151.	0.5	42
177	Eyeblink Classical Conditioning to Auditory and Olfactory Stimuli: Performance Among Older Adults With and Without the Apolipoprotein E ϵ 4 Allele. <i>Neuropsychology</i> , 2005, 19, 437-445.	1.3	11
178	Very Early Detection of Alzheimer Neuropathology and the Role of Brain Reserve in Modifying Its Clinical Expression. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2005, 18, 218-223.	2.3	145
179	Executive Control Mediates Memory's Association with Change in Instrumental Activities of Daily Living: The Freedom House Study. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 11-17.	2.6	141
180	Cognitive Deficits 3 to 6 Years Before Dementia Onset in a Population Sample: The Honolulu Asia Aging Study. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 452-455.	2.6	52
181	Correlation between tau phosphorylation sites and tangle morphology in Alzheimer's disease. <i>Psychogeriatrics</i> , 2005, 5, 22-35.	1.2	2
182	The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology. <i>Neuropathology and Applied Neurobiology</i> , 2005, 31, 270-279.	3.2	60
183	Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers. <i>Neuropathology and Applied Neurobiology</i> , 2005, 31, 439-448.	3.2	84
184	Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1528-1547.	4.3	622
185	Longitudinal Functional Alterations in Asymptomatic Women at Risk for Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2005, 15, 271-277.	2.0	26
186	Sodium ferulate prevents amyloid-beta-induced neurotoxicity through suppression of p38 MAPK and upregulation of ERK-1/2 and Akt/protein kinase B in rat hippocampus. <i>Acta Pharmacologica Sinica</i> , 2005, 26, 943-951.	6.1	69
187	Tau protein aggregation in the frontal and entorhinal cortices as a function of aging. <i>Developmental Brain Research</i> , 2005, 156, 127-138.	1.7	40
188	Apolipoprotein E and category fluency: evidence for reduced semantic access in healthy normal controls at risk for developing Alzheimer's disease. <i>Neuropsychologia</i> , 2005, 43, 647-658.	1.6	60
189	Retrieval of autobiographical memory in Alzheimer's disease: Relation to volumes of medial temporal lobe and other structures. <i>Hippocampus</i> , 2005, 15, 535-550.	1.9	117
190	APOE and other loci affect age at onset in Alzheimer's disease families with PS2 mutation. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2005, 132B, 14-20.	1.7	65
191	Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. <i>Annals of Neurology</i> , 2005, 58, 748-757.	5.3	144

#	ARTICLE	IF	CITATIONS
194	Alzheimer's associated inflammation, potential drug targets and future therapies. Journal of Neural Transmission, 2005, 112, 429-453.	2.8	92
195	Cholinergic dysfunction in vascular dementia. Current Psychiatry Reports, 2005, 7, 18-26.	4.5	41
196	Measuring Morphological and Cellular Changes in Alzheimers Dementia: A Review Emphasizing Stereology. Current Alzheimer Research, 2005, 2, 449-481.	1.4	29
197	Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology, 2005, 64, 1032-1039.	1.1	469
198	Semantic Memory Disorders in Alzheimers Disease: Clues from Semantic Priming Effects. Current Alzheimer Research, 2005, 2, 425-434.	1.4	36
199	Technology Insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI. Nature Clinical Practice Neurology, 2005, 1, 96-105.	2.5	19
200	Î²-Amyloid-Stimulated Microglia Induce Neuron Death via Synergistic Stimulation of Tumor Necrosis Factor Î± and NMDA Receptors. Journal of Neuroscience, 2005, 25, 2566-2575.	3.6	223
201	Pattern of Cerebral Hypoperfusion in Alzheimer Disease and Mild Cognitive Impairment Measured with Arterial Spin-labeling MR Imaging: Initial Experience. Radiology, 2005, 234, 851-859.	7.3	532
202	Alzheimers Disease and Neural Transplantation as Prospective Cell Therapy. Current Alzheimer Research, 2005, 2, 79-95.	1.4	60
203	Î²1 Adrenergic Receptor-Mediated Enhancement of Hippocampal CA3 Network Activity. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 552-560.	2.5	41
204	Antecedent Biomarkers of Alzheimer's Disease: The Adult Children Study. Journal of Geriatric Psychiatry and Neurology, 2005, 18, 242-244.	2.3	36
205	Cholesterol-mediated Neurite Outgrowth Is Differently Regulated between Cortical and Hippocampal Neurons*. Journal of Biological Chemistry, 2005, 280, 42759-42765.	3.4	74
206	Vascular Dementia Prevention: A Risk Factor Analysis. Cerebrovascular Diseases, 2005, 20, 91-100.	1.7	128
207	Role of biomarkers in studies of presymptomatic Alzheimer's disease. , 2005, 1, 145-151.		23
208	Functional implications of hippocampal volume and diffusivity in mild cognitive impairment. NeuroImage, 2005, 28, 1033-1042.	4.2	181
209	Current Status of Functional MR Imaging, Perfusion-Weighted Imaging, and Diffusion-Tensor Imaging in Alzheimer's Disease Diagnosis and Research. Neuroimaging Clinics of North America, 2005, 15, 853-868.	1.0	18
210	Alzheimer-type neuropathology in a 28 year old patient with iatrogenic Creutzfeldt-Jakob disease after dural grafting. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 77, 413-416.	1.9	42
211	Development of a Method for Quantification of Acrolein-Deoxyguanosine Adducts in DNA Using Isotope Dilution-Capillary LC/MS/MS and Its Application to Human Brain Tissue. Analytical Chemistry, 2005, 77, 5982-5989.	6.5	75

#	ARTICLE	IF	CITATIONS
212	Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. <i>Neurobiology of Disease</i> , 2005, 18, 32-39.	4.4	102
213	Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to β -amyloid deposition and neurotransmitter abnormalities. <i>Neurobiology of Disease</i> , 2005, 18, 602-617.	4.4	362
214	Age-related impairments in operant DMTP performance in the PS2APP mouse, a transgenic mouse model of Alzheimer's disease. <i>Behavioural Brain Research</i> , 2005, 161, 220-228.	2.2	14
215	Imaging β -amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. <i>Nuclear Medicine and Biology</i> , 2005, 32, 337-351.	0.6	38
216	mRNA methods used in dissecting gene expression of the brain. <i>Ageing Research Reviews</i> , 2005, 4, 513-528.	10.9	6
217	Transgenic models of Alzheimer's disease: Learning from animals. <i>NeuroRx</i> , 2005, 2, 423-437.	6.0	180
218	Short- and Long-Term Implicit Memory in Aging and Alzheimer's Disease. <i>Aging, Neuropsychology, and Cognition</i> , 2006, 13, 611-635.	1.3	25
220	Working-Delayed Memory Difference Detects Mild Cognitive Impairment Without Being Affected by Age and Education. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2006, 28, 528-535.	1.3	13
221	Examining the gateway to the limbic system with diffusion tensor imaging: The perforant pathway in dementia. <i>NeuroImage</i> , 2006, 30, 713-720.	4.2	110
222	Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. <i>NeuroImage</i> , 2006, 33, 94-102.	4.2	116
223	Dementia and Cerebrovascular Disease. <i>Mayo Clinic Proceedings</i> , 2006, 81, 223-230.	3.0	67
225	Imaging and In Vivo Quantitation of β -Amyloid: An Exemplary Biomarker for Alzheimer's Disease?. <i>Biological Psychiatry</i> , 2006, 59, 940-947.	1.3	25
226	Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease. <i>Neuroscience Research</i> , 2006, 54, 197-201.	1.9	274
227	Pattern of cerebral hypoperfusion in Alzheimer's disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: Initial experience. <i>International Congress Series</i> , 2006, 1290, 108-122.	0.2	5
228	Prostaglandin D2 mediates neuronal damage by amyloid- β or prions which activates microglial cells. <i>Neuropharmacology</i> , 2006, 50, 229-237.	4.1	35
229	Platelet-activating factor antagonists protect amyloid- β damaged neurons from microglia-mediated death. <i>Neuropharmacology</i> , 2006, 51, 173-181.	4.1	28
230	Impact of Neuroprotection on Incidence of Alzheimer's Disease. <i>PLoS ONE</i> , 2006, 1, e52.	2.5	11
232	The search for antecedent biomarkers of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2006, 8, 347-358.	2.6	23

#	ARTICLE	IF	CITATIONS
233	In Vivo Assessment of Iron in Huntington's Disease and Other Age-Related Neurodegenerative Brain Diseases. , 2006, , 151-177.		1
234	Patterns of prospective and retrospective memory impairment in preclinical Alzheimer's disease.. Neuropsychology, 2006, 20, 144-152.	1.3	121
235	The natural and molecular history of Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 9, 187-194.	2.6	22
236	Physiopathologie de la maladie d'Alzheimer. EMC - TraitÃ© De MÃ©decine AKOS, 2006, 1, 1-11.	0.0	0
237	Early-Life Risk Factors for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, 63-72.	1.3	222
238	CNS Gene Therapy and a Nexus of Complexity: Systems and Biology at a Crossroads. Cell Transplantation, 2006, 15, 267-273.	2.5	12
239	Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. Journal of Neurochemistry, 2006, 97, 1005-1014.	3.9	143
240	Vulnerability of Select Neuronal Types to Alzheimer's Disease. Annals of the New York Academy of Sciences, 2000, 924, 53-61.	3.8	123
241	Pathological Changes in the Parahippocampal Region in Select Non-â€œAlzheimer's Dementias. Annals of the New York Academy of Sciences, 2000, 911, 221-239.	3.8	43
242	The Parahippocampal Gyrus in Alzheimer's Disease: Clinical and Preclinical Neuroanatomical Correlates. Annals of the New York Academy of Sciences, 2000, 911, 254-274.	3.8	160
243	Exploring a Mathematical Model for the Kinetics of β^2 -Amyloid Molecular Imaging Probes through a Critical Analysis of Plaque Pathology. Molecular Imaging and Biology, 2006, 8, 151-162.	2.6	16
244	Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathologica, 2006, 111, 529-538.	7.7	146
245	The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison. Acta Neuropathologica, 2006, 112, 417-427.	7.7	32
246	Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathologica, 2006, 112, 389-404.	7.7	2,318
247	Ubiquilin 1 polymorphisms are not associated with late-onset Alzheimer's disease. Annals of Neurology, 2006, 59, 21-26.	5.3	37
248	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain, 2006, 129, 3081-3090.	7.6	291
249	Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain, 2006, 129, 2805-2807.	7.6	54
250	Filling the Gaps in the Aβ Cascade Hypothesis of Alzheimers Disease. Current Alzheimer Research, 2006, 3, 421-430.	1.4	116

#	ARTICLE	IF	CITATIONS
251	Challenges in Neuronal Apoptosis. Current Alzheimer Research, 2006, 3, 377-391.	1.4	74
252	Imaging the Earliest Stages of Alzheimers Disease. Current Alzheimer Research, 2006, 3, 529-539.	1.4	22
253	Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology, 2006, 66, 1399-1404.	1.1	115
254	Neuritic Deposits of Amyloid- β Peptide in a Subpopulation of Central Nervous System-Derived Neuronal Cells. Molecular and Cellular Biology, 2006, 26, 4982-4997.	2.3	35
255	A review of genome mutation and Alzheimer's disease. Mutagenesis, 2006, 22, 15-33.	2.6	59
256	Multi-detector CT angiography in intracranial dural AV fistula at the foramen magnum. Neurology, 2006, 66, 1404-1404.	1.1	1
257	Treating Alzheimer Disease. Archives of Neurology, 2006, 63, 926.	4.5	1
258	Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid β -Amyloid 42 in Adults With Normal Cognition. Archives of Neurology, 2006, 63, 936.	4.5	118
259	Time Will Be of the Essence in Treating Alzheimer Disease. JAMA - Journal of the American Medical Association, 2006, 296, 327.	7.4	3
260	Expression of a Familial Alzheimer's Disease-Linked Presenilin-1 Variant Enhances Perforant Pathway Lesion-Induced Neuronal Loss in the Entorhinal Cortex. Journal of Neuroscience, 2006, 26, 429-434.	3.6	27
261	Functional Neuroimaging in Memory and Memory Disturbances. Current Medical Imaging, 2006, 2, 35-57.	0.8	32
262	Increased Neurofibrillary Tangles in the Brains of Older Pedestrians Killed in Traffic Accidents. Dementia and Geriatric Cognitive Disorders, 2006, 22, 20-26.	1.5	19
263	Reduction in Mitochondrial Superoxide Dismutase Modulates Alzheimer's Disease-Like Pathology and Accelerates the Onset of Behavioral Changes in Human Amyloid Precursor Protein Transgenic Mice. Journal of Neuroscience, 2006, 26, 5167-5179.	3.6	225
264	[¹¹ C]PIB in a nondemented population. Neurology, 2006, 67, 446-452.	1.1	1,000
266	Traumatic brain injury and Alzheimer's disease: a review. Progress in Brain Research, 2007, 161, 303-316.	1.4	177
267	Longitudinal Changes in Cerebral Blood Flow in the Older Hypertensive Brain. Stroke, 2007, 38, 1766-1773.	2.0	168
268	Radioligand Development for PET Imaging of β -Amyloid (A β)-Current Status. Current Medicinal Chemistry, 2007, 14, 19-52.	2.4	126
269	Association of Increased Cortical Soluble A β 42 Levels With Diffuse Plaques After Severe Brain Injury in Humans. Archives of Neurology, 2007, 64, 541.	4.5	131

#	ARTICLE	IF	CITATIONS
270	Three-Dimensional Gray Matter Atrophy Mapping in Mild Cognitive Impairment and Mild Alzheimer Disease. Archives of Neurology, 2007, 64, 1489.	4.5	117
271	Brain structural alterations before mild cognitive impairment. Neurology, 2007, 68, 1268-1273.	1.1	143
272	Amyloid, hypometabolism, and cognition in Alzheimer disease. Neurology, 2007, 68, 501-508.	1.1	470
274	Imaging β -amyloid burden in aging and dementia. Neurology, 2007, 68, 1718-1725.	1.1	997
275	Chapter 2 Alzheimer's Disease. Blue Books of Neurology, 2007, , 33-58.	0.1	2
276	Visual Assessment Versus Quantitative Assessment of ^{11}C -PIB PET and ^{18}F -FDG PET for Detection of Alzheimer's Disease. Journal of Nuclear Medicine, 2007, 48, 547-552.	5.0	220
277	Alterations in Expression of Glutamatergic Transporters and Receptors in Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 11, 97-116.	2.6	257
278	APOE genotype and cognitive functioning in a large age-stratified population sample.. Neuropsychology, 2007, 21, 1-8.	1.3	143
279	Aluminum Induces Tau Aggregation in vitro but not in vivo. Journal of Alzheimer's Disease, 2007, 11, 419-427.	2.6	47
280	Angiocentric Glioma. American Journal of Surgical Pathology, 2007, 31, 1709-1718.	3.7	110
282	Amyloid imaging in Alzheimer's disease. Current Opinion in Neurology, 2007, 20, 398-402.	3.6	87
283	Spatial and temporal control of age-related APP processing in genomic-based β -secretase transgenic mice. Neurobiology of Aging, 2007, 28, 75-84.	3.1	14
284	Location, location, location!. Neurobiology of Aging, 2007, 28, 1481-1482.	3.1	15
285	Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by $\text{A}\beta_{1-42}$. Neuropharmacology, 2007, 53, 222-231.	4.1	45
286	An experimental approach to detecting dementia in Down syndrome: A paradigm for Alzheimer's disease. Brain and Cognition, 2007, 64, 92-103.	1.8	12
287	Clinicopathological Findings of Suicide in the Elderly: Three Cases. Suicide and Life-Threatening Behavior, 2007, 37, 648-658.	1.9	13
288	Apolipoprotein E ϵ 4 Genotype and Gender: Effects on Memory. American Journal of Geriatric Psychiatry, 2007, 15, 869-878.	1.2	21
289	NSAIDs for the Chemoprevention of Alzheimer's Disease. Sub-Cellular Biochemistry, 2007, 42, 229-248.	2.4	47

#	ARTICLE	IF	CITATIONS
290	Amyloid imaging in vivo: implications for Alzheimer's disease management. Expert Opinion on Medical Diagnostics, 2007, 1, 337-349.	1.6	3
291	Normal Pressure Hydrocephalus. Neurologic Clinics, 2007, 25, 809-832.	1.8	44
292	The Pathogenesis of Alzheimer's Disease: General Overview. , 2007, , 3-29.		1
293	Does Aluminum Contribute to Alzheimer Disease Directly, Indirectly, or At All?. Journal of Alzheimer's Disease, 2007, 11, 431-432.	2.6	3
294	Mild neuritic changes are increased in the brains of fatally injured older motor vehicle drivers. Accident Analysis and Prevention, 2007, 39, 1114-1120.	5.7	14
295	Cannabidiol in vivo blunts β -amyloid induced neuroinflammation by suppressing IL-1 β and iNOS expression. British Journal of Pharmacology, 2007, 151, 1272-1279.	5.4	235
296	Investigation of Alzheimer's disease-related pathology in community dwelling older subjects who committed suicide. Journal of Affective Disorders, 2007, 99, 127-132.	4.1	35
297	Omental Transposition in Treatment of Alzheimer Disease. Journal of the American College of Surgeons, 2007, 205, 800-804.	0.5	24
298	Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. Journal of Cellular and Molecular Medicine, 2008, 12, 38-55.	3.6	200
299	Vulnerability of the Orbitofrontal Cortex to Age-Associated Structural and Functional Brain Changes. Annals of the New York Academy of Sciences, 2007, 1121, 562-575.	3.8	63
300	Granular Tau Oligomers as Intermediates of Tau Filaments. Biochemistry, 2007, 46, 3856-3861.	2.5	254
301	Movement disorders: Neurodevelopment and neurobehavioural expression. Journal of Neural Transmission, 2007, 114, XXXIII-XLI.	2.8	3
302	Investigating the Medial Temporal Lobe in Alzheimer's Disease and Mild Cognitive Impairment, with TurboProp Diffusion Tensor Imaging, MRI-volumetry, and T2-relaxometry. Brain Imaging and Behavior, 2007, 1, 11-21.	2.1	21
303	Amyloid plaque imaging in vivo: current achievement and future prospects. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 46-50.	6.4	74
305	Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathologica, 2008, 115, 599-609.	7.7	288
306	Biphasic modulation of protein kinase C and enhanced cell toxicity by amyloid beta peptide and anoxia in neuronal cultures. Journal of Neurochemistry, 2008, 76, 758-767.	3.9	31
307	Early detection of Alzheimer's disease: a new working memory paradigm. International Journal of Geriatric Psychiatry, 2008, 23, 272-278.	2.7	21
308	Conditionally inducible tau mice "designing a better mouse model of neurodegenerative diseases. Genes, Brain and Behavior, 2008, 7, 12-27.	2.2	14

#	ARTICLE	IF	CITATIONS
309	Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. <i>BMC Neuroscience</i> , 2008, 9, 81.	1.9	199
310	Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. <i>Lancet Neurology</i> , The, 2008, 7, 129-135.	10.2	631
311	Parenchymal and vascular β -deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 1848-1862.	3.6	109
312	Amyloid imaging in Alzheimer's disease. <i>Neuropsychologia</i> , 2008, 46, 1636-1641.	1.6	66
313	Small baseline volume of left hippocampus is associated with subsequent conversion of MCI into dementia: The GÅrteborg MCI study. <i>Journal of the Neurological Sciences</i> , 2008, 272, 48-59.	0.6	74
314	Early diagnosis and treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 769-780.	2.8	24
315	Cognitive Dysfunction and Diabetes Mellitus. <i>Endocrine Reviews</i> , 2008, 29, 494-511.	20.1	670
316	Soft-diet feeding decreases dopamine release and impairs aversion learning in Alzheimer model rats. <i>Neuroscience Letters</i> , 2008, 439, 208-211.	2.1	47
317	Role of neuroendocrine pathways in cognitive decline during aging. <i>Ageing Research Reviews</i> , 2008, 7, 225-233.	10.9	61
318	I. Longitudinal changes in aging brain function. <i>Neurobiology of Aging</i> , 2008, 29, 483-496.	3.1	60
319	II. Temporal patterns of longitudinal change in aging brain function. <i>Neurobiology of Aging</i> , 2008, 29, 497-513.	3.1	32
320	Olfaction in patients with mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008, 29, 693-706.	3.1	325
321	EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease. <i>Neurobiology of Aging</i> , 2008, 29, 819-827.	3.1	125
322	Impairment of spatial memory consolidation in APP751SL mice results in cue-guided response. <i>Neurobiology of Aging</i> , 2008, 29, 1011-1021.	3.1	15
323	Anatomic localization of the transentorhinal region of the perirhinal cortex. <i>Neurobiology of Aging</i> , 2008, 29, 1591-1596.	3.1	61
324	No disease in the brain of a 115-year-old woman. <i>Neurobiology of Aging</i> , 2008, 29, 1127-1132.	3.1	69
325	What does it take to stay healthy past 100?. <i>Neurobiology of Aging</i> , 2008, 29, 1140-1142.	3.1	0
326	Neurofibrillary changes of the Alzheimer type in very elderly individuals: Neither inevitable nor benign. <i>Neurobiology of Aging</i> , 2008, 29, 1133-1136.	3.1	24

#	ARTICLE	IF	CITATIONS
327	Tau, a biological marker of neurodegenerative diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 161-172.	1.8	3
328	Neuroimaging of individuals with Downâ€™s syndrome at-risk for dementia: Evidence for possible compensatory events. NeuroImage, 2008, 39, 1324-1332.	4.2	65
329	Simplified parametric methods for [11C]PIB studies. NeuroImage, 2008, 42, 76-86.	4.2	85
330	Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. NeuroImage, 2008, 43, 430-439.	4.2	81
331	Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment. Alzheimer's and Dementia, 2008, 4, 265-270.	0.8	291
332	Active and Passive Immunotherapy for Neurodegenerative Disorders. Annual Review of Neuroscience, 2008, 31, 175-193.	10.7	237
333	Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. NeuroImage, 2008, 43, 236-244.	4.2	91
334	The Chemical Senses and Nutrition in Older Adults. Journal of Nutrition in Gerontology and Geriatrics, 2008, 27, 247-265.	1.0	63
335	Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. Archives of Neurology, 2008, 65, 1509.	4.5	923
336	Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist. Archives of Neurology, 2008, 65, 1281-3.	4.5	11
337	Medical Challenges of Improving the Quality of a Longer Life. JAMA - Journal of the American Medical Association, 2008, 299, 688.	7.4	38
338	Early parental death and late-life dementia risk: findings from the Cache County Study. Age and Ageing, 2008, 38, 340-343.	1.6	36
339	Relationships Between Expression of Apolipoprotein E and Î²-Amyloid Precursor Protein Are Altered in Proximity to Alzheimer Î²-Amyloid Plaques. Journal of Neuropathology and Experimental Neurology, 2008, 67, 773-783.	1.7	21
340	Improved predictive model for pre-symptomatic mild cognitive impairment and Alzheimer's disease. Neurological Research, 2008, 30, 1091-1096.	1.3	9
341	Role of the Neuropathology of Alzheimer Disease in Dementia in the Oldest-Old. Archives of Neurology, 2008, 65, 1211-7.	4.5	142
342	Î² Oligomers Induce Neuronal Cell Cycle Events in Alzheimer's Disease. Journal of Neuroscience, 2008, 28, 10786-10793.	3.6	126
343	Knee height and arm span. Neurology, 2008, 70, 1818-1826.	1.1	53
344	An Increase in Aβ42 in the Prefrontal Cortex is Associated with a Reversal-Learning Impairment in Alzheimers Disease Model Tg2576 APPsw Mice. Current Alzheimer Research, 2008, 5, 385-391.	1.4	29

#	ARTICLE	IF	CITATIONS
345	Incidental Lewy Body Disease and Preclinical Parkinson Disease. Archives of Neurology, 2008, 65, 1074-80.	4.5	166
346	IMAGING β^2 -AMYLOID BURDEN IN AGING AND DEMENTIA. Neurology, 2008, 70, 1649-1650.	1.1	7
347	Reduced Pathology and Improved Behavioral Performance in Alzheimer's Disease Mice Vaccinated With HSV Amplicons Expressing Amyloid- β^2 and Interleukin-4. Molecular Therapy, 2008, 16, 845-853.	8.2	49
348	Tau Aggregates: Toxic, Inert, or Protective Species?. Journal of Alzheimer's Disease, 2008, 14, 431-436.	2.6	82
349	Fluoro-2-Deoxy-D-Glucose (FDG)-PET in APOE ϵ 4 Carriers in the Australian Population. Journal of Alzheimer's Disease, 2008, 13, 137-146.	2.6	28
350	Whatever Happened to Pittsburgh Compound-A?. Alzheimer Disease and Associated Disorders, 2008, 22, 198-203.	1.3	9
351	Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies. Journal of Alzheimer's Disease, 2008, 15, 157-168.	2.6	107
352	Cerebrovascular contributions to amnesic mild cognitive impairment. , 0, , 161-171.		0
353	Propagation of Tau Misfolding from the Outside to the Inside of a Cell. Journal of Biological Chemistry, 2009, 284, 12845-12852.	3.4	1,043
354	Human Truncated Tau is Using a Different Mechanism from Amyloid- β^2 to Damage the Blood-Brain Barrier. Journal of Alzheimer's Disease, 2009, 18, 897-906.	2.6	55
355	Low Micromolar Zinc Accelerates the Fibrillization of Human Tau via Bridging of Cys-291 and Cys-322. Journal of Biological Chemistry, 2009, 284, 34648-34657.	3.4	168
356	Functional Magnetic Resonance Imaging of Compensatory Neural Recruitment in Aging and Risk for Alzheimer's Disease: Review and Recommendations. Dementia and Geriatric Cognitive Disorders, 2009, 27, 1-10.	1.5	52
357	Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia. Current Psychiatry Reviews, 2009, 5, 73-92.	0.9	112
358	Influence of Cognitive Status, Age, and APOE-4 Genetic Risk on Brain FDDNP Positron-Emission Tomography Imaging in Persons Without Dementia. Archives of General Psychiatry, 2009, 66, 81.	12.3	56
359	Episodic memory loss is related to hippocampal-mediated β -amyloid deposition in elderly subjects. Brain, 2009, 132, 1310-1323.	7.6	596
360	The Role of the Human Hippocampus in Odor-Place Associative Memory. Chemical Senses, 2009, 34, 513-521.	2.0	25
361	Mediterranean Diet and Late-Life Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 686.	7.4	33
362	Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiology of Disease, 2009, 34, 107-112.	4.4	177

#	ARTICLE	IF	CITATIONS
363	Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral A β assembly forms throughout life. <i>Neurobiology of Disease</i> , 2009, 36, 293-302.	4.4	117
364	Apolipoprotein E ϵ -dependent accumulation of Alzheimer disease ϵ -related lesions begins in middle age. <i>Annals of Neurology</i> , 2009, 65, 650-657.	5.3	250
365	Triple ϵ -transgenic Alzheimer's disease mice exhibit region ϵ -specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. <i>Glia</i> , 2009, 57, 54-65.	4.9	199
366	Tripchlorolide protects neuronal cells from microglia ϵ -mediated β -amyloid neurotoxicity through inhibiting NF κ B and JNK signaling. <i>Glia</i> , 2009, 57, 1227-1238.	4.9	64
367	Subjective cognitive impairment: increased prefrontal cortex activation compared to controls during an encoding task. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 865-874.	2.7	73
368	Entorhinal cortex structure and functional MRI response during an associative verbal memory task. <i>Human Brain Mapping</i> , 2009, 30, 3981-3992.	3.6	37
369	In vitro and in ϵ -vivo Staining Characteristics of Small, Fluorescent, A β 42 ϵ -Binding <scp>D</scp> ϵ -Enantiomeric Peptides in Transgenic AD Mouse Models. <i>ChemMedChem</i> , 2009, 4, 276-282.	3.2	60
370	Cerebrospinal fluid tau and ptau ₁₈₁ increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2009, 1, 371-380.	6.9	315
371	Evidence of angiogenic vessels in Alzheimer ϵ -TM's disease. <i>Journal of Neural Transmission</i> , 2009, 116, 587-597.	2.8	126
372	Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies. <i>Acta Neuropathologica</i> , 2009, 118, 71-86.	7.7	42
373	Classification and basic pathology of Alzheimer disease. <i>Acta Neuropathologica</i> , 2009, 118, 5-36.	7.7	805
374	Evaluation of Tracer Kinetic Models for Analysis of [18F]FDDNP Studies. <i>Molecular Imaging and Biology</i> , 2009, 11, 322-333.	2.6	20
375	Amyloid Imaging in Alzheimer ϵ -TM's Disease and Other Dementias. <i>Brain Imaging and Behavior</i> , 2009, 3, 246-261.	2.1	32
376	A novel touchscreen-automated paired-associate learning (PAL) task sensitive to pharmacological manipulation of the hippocampus: a translational rodent model of cognitive impairments in neurodegenerative disease. <i>Psychopharmacology</i> , 2009, 205, 157-168.	3.1	105
377	Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. <i>Nature</i> , 2009, 461, 916-922.	27.8	567
378	Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2009, 24, 95-121.	1.9	245
379	Age, Neuropathology, and Dementia. <i>New England Journal of Medicine</i> , 2009, 360, 2302-2309.	27.0	767
380	Contribution of neural networks to Alzheimer disease's progression. <i>Brain Research Bulletin</i> , 2009, 80, 309-314.	3.0	53

#	ARTICLE	IF	CITATIONS
381	Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. <i>Neurobiology of Aging</i> , 2009, 30, 1026-1036.	3.1	558
383	Brain lesions comprised of aluminum-rich cells that lack microtubules may be associated with the cognitive deficit of Alzheimer's disease. <i>NeuroToxicology</i> , 2009, 30, 1059-1069.	3.0	67
384	Prospective and retrospective memory in Alzheimer's disease and vascular dementia: Similar patterns of impairment. <i>Journal of the Neurological Sciences</i> , 2009, 283, 235-239.	0.6	22
386	Alzheimer disease neuropathology in the oldest old. <i>Nature Reviews Neurology</i> , 2009, 5, 411-412.	10.1	9
387	Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. <i>NeuroImage</i> , 2009, 47, 1678-1690.	4.2	201
388	Bivariate Heritability of Total and Regional Brain Volumes. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 218-223.	1.3	27
389	Comparison of Risk Factor Profiles in Incidental Lewy Body Disease and Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 1114-9.	4.5	34
390	False Recognition Correlates with Amyloid- β 42 but not with Total Tau in Cerebrospinal Fluid of Patients with Dementia and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 157-165.	2.6	24
391	Characterizing multiple memory deficits and their relation to everyday functioning in individuals with mild cognitive impairment.. <i>Neuropsychology</i> , 2009, 23, 168-177.	1.3	205
392	Recent Advances in Visualizing Alzheimers Plaques by Magnetic Resonance Imaging. <i>Current Medical Imaging</i> , 2009, 5, 2-9.	0.8	8
393	β -Amyloid: A Disease Target or a Synaptic Regulator Affecting Age-Related Neurotransmitter Changes?. <i>Current Pharmaceutical Design</i> , 2010, 16, 672-683.	1.9	30
394	Evaluation of Cumulative Lead Dose and Longitudinal Changes in Structural Magnetic Resonance Imaging in Former Organolead Workers. <i>Journal of Occupational and Environmental Medicine</i> , 2010, 52, 407-414.	1.7	15
395	Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future. <i>Future Neurology</i> , 2010, 5, 411-420.	0.5	4
396	In Vivo Structural Neuroanatomy of Corpus Callosum in Alzheimer's Disease and Mild Cognitive Impairment Using Different MRI Techniques: A Review. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 67-95.	2.6	124
397	Neuroimaging Through the Course of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 273-290.	2.6	19
398	Semantic networks for odors and colors in Alzheimer's disease.. <i>Neuropsychology</i> , 2010, 24, 291-299.	1.3	15
399	Applied hybrid model in the neuropsychological diagnosis of the Alzheimer's disease: a decision making study case. <i>International Journal of Social Humanistic Computing</i> , 2010, 1, 331.	0.3	10
400	Emergence and natural selection of drug-resistant prions. <i>Molecular BioSystems</i> , 2010, 6, 1115.	2.9	48

#	ARTICLE	IF	CITATIONS
401	Graph theoretical analysis of structural and functional connectivity MRI in normal and pathological brain networks. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2010, 23, 409-421.	2.0	245
402	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. <i>Lancet Neurology</i> , The, 2010, 9, 119-128.	10.2	3,792
403	Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: Experimental approaches and future clinical applications. <i>Experimental Gerontology</i> , 2010, 45, 15-22.	2.8	34
404	Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. <i>Annals of Neurology</i> , 2010, 68, 535-540.	5.3	148
405	Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. <i>Annals of Neurology</i> , 2010, 68, 540-545.	5.3	69
406	Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. <i>Annals of Neurology</i> , 2010, 68, 446-453.	5.3	128
407	Automated production of [¹⁸ F]FDDNP using a TRACERlab MX ^{FDG} . <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2010, 53, 208-212.	1.0	3
408	Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. <i>Journal of Nutritional Biochemistry</i> , 2010, 21, 364-373.	4.2	184
409	Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease. <i>Applied Radiation and Isotopes</i> , 2010, 68, 1066-1072.	1.5	15
410	ORIGINAL ARTICLE: Computerized visuo-spatial memory test as a supplementary screening test for dementia. <i>Psychogeriatrics</i> , 2010, 10, 77-82.	1.2	25
411	Burden of Neurodegenerative Diseases in a Cohort of Medical Examiner Subjects*. <i>Journal of Forensic Sciences</i> , 2010, 55, 642-645.	1.6	8
412	The progression of pathology in Parkinson's disease. <i>Annals of the New York Academy of Sciences</i> , 2010, 1184, 188-195.	3.8	214
413	Alterations of Zinc Transporter Proteins ZnT1, ZnT4 and ZnT6 in Preclinical Alzheimer's Disease Brain. <i>Brain Pathology</i> , 2010, 20, 343-350.	4.1	84
414	Mitotic Epitopes are Incorporated into Age-Dependent Neurofibrillary Tangles in Niemann-Pick Disease Type C. <i>Brain Pathology</i> , 2010, 20, 367-377.	4.1	14
415	NSAIDs may protect against age-related brain atrophy. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, .	3.4	14
417	Neurofibrillary Tangles. , 2010, , 265-269.		4
418	A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. <i>Brain</i> , 2010, 133, 1163-1172.	7.6	215
419	Yamaguchi Fox-Pigeon Imitation Test: A Rapid Test for Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 254-258.	1.5	27

#	ARTICLE	IF	CITATIONS
420	Entorhinal cortex volume in older adults: Reliability and validity considerations for three published measurement protocols. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 846-855.	1.8	22
421	The Challenge and Public Health Implications of Alzheimer Overdiagnosis in the Oldest Oldâ€”Reply. <i>Archives of Neurology</i> , 2010, 67, 899.	4.5	0
422	The Challenge and Public Health Implications of Alzheimer Overdiagnosis in the Oldest Old. <i>Archives of Neurology</i> , 2010, 67, 899.	4.5	2
423	Mouse Models of Neurodegenerative Diseases: Criteria and General Methodology. <i>Methods in Molecular Biology</i> , 2010, 602, 323-345.	0.9	22
424	Quantitative Characterization of Heparin Binding to Tau Protein. <i>Journal of Biological Chemistry</i> , 2010, 285, 3592-3599.	3.4	96
425	Worldwide distribution of <i>PSEN1</i> Met146Leu mutation. <i>Neurology</i> , 2010, 74, 798-806.	1.1	38
426	Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. <i>Archives of Neurology</i> , 2010, 67, 1473.	4.5	376
427	Hypothermia and Alzheimers Disease Neuropathogenic Pathways. <i>Current Alzheimer Research</i> , 2010, 7, 717-725.	1.4	30
428	Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers. <i>Brain</i> , 2010, 133, 3685-3698.	7.6	94
429	Amyloid PET Ligands for Dementia. <i>PET Clinics</i> , 2010, 5, 33-53.	3.0	23
430	Cerebrospinal fluid biomarkers of Alzheimerâ€™s disease. <i>Biomarkers in Medicine</i> , 2010, 4, 51-63.	1.4	65
431	Prion-like disorders: blurring the divide between transmissibility and infectivity. <i>Journal of Cell Science</i> , 2010, 123, 1191-1201.	2.0	268
432	Amyloid load in nondemented brains correlates with APOE e4. <i>Neuroscience Letters</i> , 2010, 473, 168-171.	2.1	76
433	White matter diffusion alterations in normal women at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2010, 31, 1122-1131.	3.1	93
434	AÎ² accumulation in choroid plexus is associated with mitochondrial-induced apoptosis. <i>Neurobiology of Aging</i> , 2010, 31, 1569-1581.	3.1	63
435	Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2010, 31, 1669-1678.	3.1	95
436	What's Next?. <i>Neurobiology of Aging</i> , 2010, 31, 1493.	3.1	0
437	¹¹ C-PIB PET in subjective cognitive impairment. <i>European Psychiatry</i> , 2010, 25, 123-125.	0.2	34

#	ARTICLE	IF	CITATIONS
438	White matter is altered with parental family history of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2010, 6, 394-403.	0.8	109
439	The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans. <i>Alzheimer's and Dementia</i> , 2010, 6, 202.	0.8	443
440	fMRI congruous word repetition effects reflect memory variability in normal elderly. <i>Neurobiology of Aging</i> , 2010, 31, 1975-1990.	3.1	14
441	Callosal atrophy in mild cognitive impairment and Alzheimer's disease: Different effects in different stages. <i>NeuroImage</i> , 2010, 49, 141-149.	4.2	100
442	FDDNP binding using MR derived cortical surface maps. <i>NeuroImage</i> , 2010, 49, 240-248.	4.2	23
443	Simplified parametric methods for [18F]FDDNP studies. <i>NeuroImage</i> , 2010, 49, 433-441.	4.2	7
444	A β ² Accelerates the Spatiotemporal Progression of Tau Pathology and Augments Tau Amyloidosis in an Alzheimer Mouse Model. <i>American Journal of Pathology</i> , 2010, 177, 1977-1988.	3.8	179
445	Midlife predictors of Alzheimer's disease. <i>Maturitas</i> , 2010, 65, 131-137.	2.4	58
446	Review Article: Genetics of Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2010, 23, 213-227.	2.3	748
447	Aging, Brain Disease, and Reserve: Implications for Delirium. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 117-127.	1.2	97
448	Early detection of Alzheimer's based on intrinsic measurements. , 2011, , .		1
449	Can aerobic exercise protect against dementia?. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 6.	6.2	16
450	Developing methodologies to evaluate benefits and costs of Arterial Spin Labeling in Alzheimer's Disease. , 2011, , .		0
451	Age, gender, and education effects on vocabulary measures in Greek. <i>Aphasiology</i> , 2011, 25, 475-491.	2.2	49
452	Impacts of Methylxanthines and Adenosine Receptors on Neurodegeneration: Human and Experimental Studies. <i>Handbook of Experimental Pharmacology</i> , 2011, , 267-310.	1.8	71
453	Relationships between cognitive function and frontal grey matter volumes and thickness in middle aged and early old-aged adults: The PATH Through Life Study. <i>NeuroImage</i> , 2011, 55, 845-855.	4.2	28
454	Differential effects of age and history of hypertension on regional brain volumes and iron. <i>NeuroImage</i> , 2011, 54, 750-759.	4.2	63
455	Correlation between baseline regional gray matter volume and global gray matter volume decline rate. <i>NeuroImage</i> , 2011, 54, 743-749.	4.2	12

#	ARTICLE	IF	CITATIONS
456	Brain Biochemical Correlates of the Plasma Homocysteine Level: A Proton Magnetic Resonance Spectroscopy Study in the Elderly Subjects. American Journal of Geriatric Psychiatry, 2011, 19, 618-626.	1.2	19
457	Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study. Alzheimer's Research and Therapy, 2011, 3, 5.	6.2	22
458	Methylxanthines. Handbook of Experimental Pharmacology, 2011, , .	1.8	22
459	Tau Accumulation Causes Mitochondrial Distribution Deficits in Neurons in a Mouse Model of Tauopathy and in Human Alzheimer's Disease Brain. American Journal of Pathology, 2011, 179, 2071-2082.	3.8	224
460	Detection of age-dependent working memory deterioration in APP751SL mice. Behavioural Brain Research, 2011, 218, 129-137.	2.2	7
461	Lifespan brain activity, β -amyloid, and Alzheimer's disease. Trends in Cognitive Sciences, 2011, 15, 520-526.	7.8	186
462	Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy. Neurobiology of Aging, 2011, 32, 590-603.	3.1	94
463	Cingulum fiber diffusivity and CSF T-tau in patients with subjective and mild cognitive impairment. Neurobiology of Aging, 2011, 32, 581-589.	3.1	49
464	Anti- β Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift. Neuron, 2011, 69, 203-213.	8.1	350
465	The Many Faces of Tau. Neuron, 2011, 70, 410-426.	8.1	734
466	Amyloid- β and α , biomarkers in Parkinson's disease-“dementia. Journal of the Neurological Sciences, 2011, 310, 25-30.	0.6	36
467	The Merits of FDDNP-PET Imaging in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 135-145.	2.6	51
468	Commentary on “Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.” Addressing the challenge of Alzheimer's disease in the 21st century. Alzheimer's and Dementia, 2011, 7, 335-337.	0.8	26
469	Research Towards Tau Imaging. Journal of Alzheimer's Disease, 2011, 26, 147-157.	2.6	39
470	Pathological Stages of Abnormally Processed Tau Protein During Its Aggregation into Fibrillary Structures in Alzheimer's Disease. , 0, , .		1
471	Currently Available Neuroimaging Approaches in Alzheimer Disease (AD) Early Diagnosis. , 2011, , .		1
472	Neuroimaging Measures as Endophenotypes in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-15.	2.0	49
473	Imaging the Alzheimer Brain. Journal of Alzheimer's Disease, 2011, 26, 1-27.	2.6	41

#	ARTICLE	IF	CITATIONS
474	Plasmalogen Deficit: A New and Testable Hypothesis for the Etiology of Alzheimer's Disease. , 0, , .		5
475	Alzheimer's Diseases: Towards Biomarkers for an Early Diagnosis. , 2011, , .		0
476	Detection of Soluble Amyloid- β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-8.	2.0	17
477	Knowing Me, Knowing You: Can a Knowledge of Risk Factors for Alzheimer's Disease Prove Useful in Understanding the Pathogenesis of Parkinson's Disease?. Journal of Alzheimer's Disease, 2011, 25, 395-415.	2.6	24
478	Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PLoS ONE, 2011, 6, e16032.	2.5	152
479	Multiple Indices of Diffusion Identifies White Matter Damage in Mild Cognitive Impairment and Alzheimer's Disease. PLoS ONE, 2011, 6, e21745.	2.5	108
480	A Novel Pathogenic PSEN1 Mutation in a Family with Alzheimer's Disease: Phenotypical and Neuropathological Features. Journal of Alzheimer's Disease, 2011, 25, 425-431.	2.6	14
481	Dementia and the Default Mode. Current Alzheimer Research, 2011, 8, 361-365.	1.4	38
482	Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years. Journal of Neuropathology and Experimental Neurology, 2011, 70, 960-969.	1.7	1,562
483	Which Memory System is Impaired First in Alzheimer's Disease?. Journal of Alzheimer's Disease, 2011, 27, 11-22.	2.6	114
484	Prediction of Preclinical Alzheimer's Disease: Longitudinal Rates of Change in Cognition. Journal of Alzheimer's Disease, 2011, 25, 707-717.	2.6	39
485	Physical exercise alleviates debilities of normal aging and Alzheimer's disease. Acta Neurologica Scandinavica, 2011, 123, 221-238.	2.1	82
486	Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia, 2011, 49, 2384-2390.	1.6	139
487	Intracranial volume and dementia: Some evidence in support of the cerebral reserve hypothesis. Brain Research, 2011, 1385, 151-162.	2.2	22
488	Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. International Journal of Geriatric Psychiatry, 2012, 27, 364-374.	2.7	86
489	De rol van de parietale kwab in de vroege fase van de ziekte van Alzheimer. Neuropraxis, 2011, 15, 113-120.	0.1	0
490	Alzheimer's Disease: The Challenge of the Second Century. Science Translational Medicine, 2011, 3, 77sr1.	12.4	1,109
491	Dementia among older in-hospital patients with obstructive airway disease. Zeitschrift Fur Gerontologie Und Geriatrie, 2011, 44, 240-244.	1.8	11

#	ARTICLE	IF	CITATIONS
492	The pathological process underlying Alzheimer's disease in individuals under thirty. <i>Acta Neuropathologica</i> , 2011, 121, 171-181.	7.7	654
493	Tau pathology in children and young adults: can you still be unconditionally baptist?. <i>Acta Neuropathologica</i> , 2011, 121, 145-147.	7.7	63
494	Alzheimer's pathogenesis: is there neuron-to-neuron propagation?. <i>Acta Neuropathologica</i> , 2011, 121, 589-595.	7.7	297
495	Opportunities and challenges in developing Alzheimer disease therapeutics. <i>Acta Neuropathologica</i> , 2011, 122, 543-549.	7.7	47
496	A computer-automated touchscreen paired-associates learning (PAL) task for mice: impairments following administration of scopolamine or dicyclomine and improvements following donepezil. <i>Psychopharmacology</i> , 2011, 214, 537-548.	3.1	61
497	Mechanisms of Neural and Behavioral Dysfunction in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2011, 43, 163-179.	4.0	15
498	Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions. <i>Neurotoxicity Research</i> , 2011, 19, 211-234.	2.7	25
499	CRP gene variation affects early development of Alzheimer's disease-related plaques. <i>Journal of Neuroinflammation</i> , 2011, 8, 96.	7.2	14
500	Amyloid- β associated cortical thinning in clinically normal elderly. <i>Annals of Neurology</i> , 2011, 69, 1032-1042.	5.3	306
501	Pathogens and Chronic or Long-Term Neurologic Disorders. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2011, 11, 40-52.	0.7	8
502	Terminal decline and practice effects in older adults without dementia. <i>Neurology</i> , 2011, 77, 722-730.	1.1	58
503	Effects of demographic variables and health status on brief vocabulary measures in Greek. <i>Aphasiology</i> , 2011, 25, 492-504.	2.2	21
504	Alzheimer's Disease "Not an Exaggeration of Healthy Aging. <i>Indian Journal of Psychological Medicine</i> , 2011, 33, 106-114.	1.5	17
505	Fall Risk Assessment Among Older Adults With Mild Alzheimer Disease. <i>Journal of Geriatric Physical Therapy</i> , 2011, 34, 19-27.	1.1	28
506	Corpus Callosum Atrophy in Patients with Mild Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2011, 8, 476-482.	1.4	44
507	Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post-mortem study. <i>Brain</i> , 2011, 134, 2969-2981.	7.6	128
508	Neocortical and hippocampal amyloid- β and tau measures associate with dementia in the oldest-old. <i>Brain</i> , 2011, 134, 3708-3715.	7.6	82
509	Brain Amyloid Imaging. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1733-1740.	5.0	226

#	ARTICLE	IF	CITATIONS
510	Towards the Applied Hybrid Model in Decision Making: A Neuropsychological Diagnosis of Alzheimer's Disease Study Case. International Journal of Computational Intelligence Systems, 2011, 4, 89-99.	2.7	20
511	Common Alzheimer's Disease Risk Variant Within the <i>CLU</i> Gene Affects White Matter Microstructure in Young Adults. Journal of Neuroscience, 2011, 31, 6764-6770.	3.6	157
512	Amyloid Imaging with ¹⁸ F-Florbetaben in Alzheimer Disease and Other Dementias. Journal of Nuclear Medicine, 2011, 52, 1210-1217.	5.0	311
513	Amyloid imaging. International Psychogeriatrics, 2011, 23, S41-S49.	1.0	29
514	Longitudinal modeling of frontal cognition in <i>APOE</i> ϵ 4 homozygotes, heterozygotes, and noncarriers. Neurology, 2011, 76, 1383-1388.	1.1	83
515	Early Astrocytic Atrophy in the Entorhinal Cortex of a Triple Transgenic Animal Model of Alzheimer's Disease. ASN Neuro, 2011, 3, AN20110025.	2.7	170
516	Neuropathological Profile of Mild Cognitive Impairment From a Population Perspective. Alzheimer Disease and Associated Disorders, 2012, 26, 205-212.	1.3	16
517	Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomarkers in Medicine, 2012, 6, 455-476.	1.4	100
518	β -Amyloid burden in healthy aging. Neurology, 2012, 78, 387-395.	1.1	338
519	Prediction of Cognitive Decline by Positron Emission Tomography of Brain Amyloid and Tau. Archives of Neurology, 2012, 69, 215.	4.5	66
520	Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB Journal, 2012, 26, 1946-1959.	0.5	420
521	Geographical variation in dementia: systematic review with meta-analysis. International Journal of Epidemiology, 2012, 41, 1012-1032.	1.9	142
522	Alzheimer's Disease Risk Gene, <i>GAB2</i> , is Associated with Regional Brain Volume Differences in 755 Young Healthy Twins. Twin Research and Human Genetics, 2012, 15, 286-295.	0.6	16
523	Metabolite Investigation in Both Anterior and Posterior Cingulate Gyri in Alzheimer's Disease Spectrum Using 3-Tesla MR Spectroscopy. Dementia and Geriatric Cognitive Disorders, 2012, 33, 149-155.	1.5	24
524	Cognitive Decline and Dementia in the Oldest-Old. Rambam Maimonides Medical Journal, 2012, 3, e0026.	1.0	43
525	APOE4 predicts amyloid- β in cortical brain biopsy but not idiopathic normal pressure hydrocephalus. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1119-1124.	1.9	23
526	Alzheimer's Disease, Cerebrovascular Disease, and the β -amyloid Cascade. Canadian Journal of Neurological Sciences, 2012, 39, 712-728.	0.5	141
527	Baseline Cardiovascular Risk Predicts Subsequent Changes in Resting Brain Function. Stroke, 2012, 43, 1542-1547.	2.0	39

#	ARTICLE	IF	CITATIONS
528	Medial perirhinal cortex disambiguates confusable objects. <i>Brain</i> , 2012, 135, 3757-3769.	7.6	83
529	Peptides for Therapy and Diagnosis of Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2012, 18, 755-767.	1.9	102
530	Recent Advances in Imaging Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S313-S327.	2.6	21
531	Evolutional Aspects of Alzheimer's Disease Pathogenesis. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S155-S161.	2.6	34
533	Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. <i>Journal of Parkinson's Disease</i> , 2012, 2, 57-65.	2.8	38
534	Biochemical Isolation of Insoluble Tau in Transgenic Mouse Models of Tauopathies. <i>Methods in Molecular Biology</i> , 2012, 849, 473-491.	0.9	33
535	Molecular Neuroimaging in Alzheimer's Disease. <i>Neuroimaging Clinics of North America</i> , 2012, 22, 57-65.	1.0	17
536	Alzheimer's disease: Pathogenesis and prevention. <i>Alzheimer's and Dementia</i> , 2012, 8, 227-233.	0.8	87
537	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 795-804.	27.0	3,005
538	Characterization of the novel protein P9TLDR (temporal lobe down-regulated) with a brain-specific gene expression modality in Alzheimer's disease brain. <i>FEBS Letters</i> , 2012, 586, 4357-4361.	2.8	2
539	Insulin and IGF-1 signalling: longevity, protein homeostasis and Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2012, 40, 721-727.	3.4	117
540	The Frontal Assessment Battery in the Differential Diagnosis of Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2012, 25, 201-207.	2.3	21
541	Novel Imaging Strategies for Assessment of Cerebrovascular Involvement. <i>Mount Sinai Journal of Medicine</i> , 2012, 79, 674-682.	1.9	0
542	[18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β^2 detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. <i>Acta Neuropathologica</i> , 2012, 124, 833-845.	7.7	75
543	Serum Biomarkers of Neurologic Injury in Cardiac Operations. <i>Annals of Thoracic Surgery</i> , 2012, 94, 1026-1033.	1.3	33
544	Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology. , 2012, 8, 343-351.		20
545	National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, 1-13.	0.8	1,968
546	Characterizing the Preclinical Stages of Alzheimer's Disease and the Prospect of Presymptomatic Intervention. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S405-S416.	2.6	73

#	ARTICLE	IF	CITATIONS
547	Metabonomic Profiling of TASTPM Transgenic Alzheimer's Disease Mouse Model. <i>Journal of Proteome Research</i> , 2012, 11, 5903-5913.	3.7	57
548	Modeling regional vulnerability to Alzheimer pathology. <i>Neurobiology of Aging</i> , 2012, 33, 1556-1563.	3.1	11
549	Age- and genotype-related neurophysiologic reactivity to oxidative stress in healthy adults. <i>Neurobiology of Aging</i> , 2012, 33, 839.e11-839.e21.	3.1	7
550	Fluorine-18 labeling of three novel d-peptides by conjugation with N-succinimidyl-4-[18F]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography. <i>Nuclear Medicine and Biology</i> , 2012, 39, 315-323.	0.6	16
551	Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. <i>Progress in Neurobiology</i> , 2012, 97, 38-51.	5.7	153
552	sAPP \pm rescues deficits in amyloid precursor protein knockout mice following focal traumatic brain injury. <i>Journal of Neurochemistry</i> , 2012, 122, 208-220.	3.9	60
553	Should Alzheimer's disease be equated with human brain ageing?: A maladaptive interaction between brain evolution and senescence. <i>Ageing Research Reviews</i> , 2012, 11, 104-122.	10.9	18
554	Abnormal event-related potentials in young and middle-aged adults with the ApoE ϵ 4 allele. <i>International Journal of Psychophysiology</i> , 2012, 83, 276-281.	1.0	11
555	Structural imaging in early pre-states of dementia. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 317-324.	3.8	7
556	White matter integrity and vulnerability to Alzheimer's disease: Preliminary findings and future directions. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 416-422.	3.8	132
557	Human fetal tau protein isoform: Possibilities for Alzheimer's disease treatment. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 1290-1294.	2.8	29
558	Individuals at risk for Alzheimer's disease show differential patterns of ERP brain activation during odor identification. <i>Behavioral and Brain Functions</i> , 2012, 8, 37.	3.3	22
559	Apolipoprotein E, Not Fibrillar β -Amyloid, Reduces Cerebral Glucose Metabolism in Normal Aging. <i>Journal of Neuroscience</i> , 2012, 32, 18227-18233.	3.6	146
560	Involvement of the β -Secretase-Mediated EphA4 Signaling Pathway in Synaptic Pathogenesis of Alzheimer's Disease. <i>Brain Pathology</i> , 2012, 22, 776-787.	4.1	28
561	Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. <i>BMJ: British Medical Journal</i> , 2012, 344, d7622-d7622.	2.3	610
562	Vascular dementia: Different forms of vessel disorders contribute to the development of dementia in the elderly brain. <i>Experimental Gerontology</i> , 2012, 47, 816-824.	2.8	179
563	Development of Positron Emission Tomography β -Amyloid Plaque Imaging Agents. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 423-432.	4.6	155
564	Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant. <i>NeuroImage</i> , 2012, 59, 1152-1160.	4.2	137

#	ARTICLE	IF	CITATIONS
565	Structural and diffusion MRI measures of the hippocampus and memory performance. <i>NeuroImage</i> , 2012, 63, 1782-1789.	4.2	88
566	In vitro characterization of [18F]-florbetaben, an A β imaging radiotracer. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1042-1048.	0.6	54
567	The Molecular Pathology of Alzheimer's Disease. <i>Neuroimaging Clinics of North America</i> , 2012, 22, 11-22.	1.0	51
568	Long Night's Journey into the Day: Amyloid- β Imaging in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S349-S359.	2.6	21
569	The Basal Forebrain Cholinergic Projection System in Mice. , 2012, , 684-718.		121
570	Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 21.	6.2	29
571	Recent Alzheimer's disease research highlights. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 14.	6.2	0
572	CSF T-Tau/A β 42 Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e37720.	2.5	84
573	Genotype-Specific Differences between Mouse CNS Stem Cell Lines Expressing Frontotemporal Dementia Mutant or Wild Type Human Tau. <i>PLoS ONE</i> , 2012, 7, e39328.	2.5	8
574	Development of a Small D-Enantiomeric Alzheimer's Amyloid- β Binding Peptide Ligand for Future In Vivo Imaging Applications. <i>PLoS ONE</i> , 2012, 7, e41457.	2.5	23
575	Human P301L-Mutant Tau Expression in Mouse Entorhinal-Hippocampal Network Causes Tau Aggregation and Presynaptic Pathology but No Cognitive Deficits. <i>PLoS ONE</i> , 2012, 7, e45881.	2.5	111
576	Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials. <i>PLoS ONE</i> , 2012, 7, e47739.	2.5	62
577	Striatal Amyloid Plaque Density Predicts Braak Neurofibrillary Stage and Clinicopathological Alzheimer's Disease: Implications for Amyloid Imaging. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 869-876.	2.6	65
578	Neocortical-hippocampal dynamics of working memory in healthy and diseased brain states based on functional connectivity. <i>Frontiers in Human Neuroscience</i> , 2012, 6, 36.	2.0	25
579	APOE Genotype and Entorhinal Cortex Volume in Non-Demented Community-Dwelling Adults in Midlife and Early Old Age. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 935-942.	2.6	22
580	Estimating the Temporal Evolution of Alzheimer's Disease Pathology with Autopsy Data. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 23-32.	2.6	5
581	CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. <i>Neurology</i> , 2012, 78, 1568-1575.	1.1	208
582	Assessment of dementia risk in aging adults using both FDG-PET and FDDNP-PET imaging. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 1017-1027.	2.7	6

#	ARTICLE	IF	CITATIONS
583	A potential role for zinc alterations in the pathogenesis of Alzheimer's disease. <i>BioFactors</i> , 2012, 38, 98-106.	5.4	29
584	Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 621-631.	6.4	208
585	Comparison of 11C-PiB and 18F-florbetaben for A β imaging in ageing and Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 983-989.	6.4	161
586	Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 341-350.	3.2	30
587	Post-mortem findings in 10 patients with presumed normal-pressure hydrocephalus and review of the literature. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 72-86.	3.2	82
588	Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice. <i>Experimental Neurology</i> , 2012, 233, 767-775.	4.1	70
589	Widespread Tau and Amyloid β Pathology Many Years After a Single Traumatic Brain Injury in Humans. <i>Brain Pathology</i> , 2012, 22, 142-149.	4.1	507
590	A randomized controlled trial investigating the effect of Pycnogenol and BacopaCDRI08 herbal medicines on cognitive, cardiovascular, and biochemical functioning in cognitively healthy elderly people: the Australian Research Council Longevity Intervention (ARCLI) study protocol (ANZCTR12611000487910). <i>Nutrition Journal</i> , 2012, 11, 11.	3.4	47
591	Amyloid- β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 202-208.	6.4	40
592	A β Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 209-219.	6.4	55
593	Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. <i>Acta Neuropathologica</i> , 2012, 123, 433-447.	7.7	78
594	Altered Brain Uptake of Therapeutics in a Triple Transgenic Mouse Model of Alzheimer's Disease. <i>Pharmaceutical Research</i> , 2013, 30, 2868-2879.	3.5	53
595	Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden. <i>Neurobiology of Aging</i> , 2013, 34, 2835-2842.	3.1	26
597	APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1322-1335.	6.1	98
598	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. <i>Journal of Neurology</i> , 2013, 260, 640-650.	3.6	50
599	A Quantum Dot Probe Conjugated with A β Antibody for Molecular Imaging of Alzheimer's Disease in a Mouse Model. <i>Cellular and Molecular Neurobiology</i> , 2013, 33, 759-765.	3.3	29
600	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 104-114.	6.4	170
601	TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. <i>Acta Neuropathologica</i> , 2013, 126, 51-57.	7.7	82

#	ARTICLE	IF	CITATIONS
602	Aluminum Involvement in the Progression of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 7-43.	2.6	101
603	Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: Can we reconcile the evidence?. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013, 88, 61-70.	2.2	74
604	Pathology of clinical and preclinical Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 137-145.	3.2	51
605	Contemplating Alzheimer's Disease and the Contribution of White Matter Hyperintensities. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 415.	4.2	106
606	Cerebral amyloid PET imaging in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2013, 126, 643-657.	7.7	99
607	Glutamine synthetase in astrocytes from entorhinal cortex of the triple transgenic animal model of Alzheimer's disease is not affected by pathological progression. <i>Biogerontology</i> , 2013, 14, 777-787.	3.9	26
608	Biomarker Modeling of Alzheimer's Disease. <i>Neuron</i> , 2013, 80, 1347-1358.	8.1	773
609	Short-term treatment with tolafenamic acid improves cognitive functions in Alzheimer's disease mice. <i>Neurobiology of Aging</i> , 2013, 34, 2421-2430.	3.1	40
610	Endogenous Tau Aggregates in Oligodendrocytes of rTg4510 Mice Induced by Human P301L Tau. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 589-600.	2.6	11
611	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. <i>Lancet Neurology</i> , The, 2013, 12, 207-216.	10.2	3,378
612	Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 3356-3362.	3.0	29
613	Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2564-2573.	3.1	55
614	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 957-965.	10.2	471
615	Vascular Aspects of Cognitive Impairment and Dementia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1696-1706.	4.3	124
616	Type 2 Diabetes and Cognitive Compromise. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013, 42, 489-501.	3.2	37
617	Odor identification and cognitive function in the Beaver Dam Offspring Study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 669-676.	1.3	29
618	Caspase-6 as a novel early target in the treatment of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2013, 37, 2005-2018.	2.6	49
619	Therapeutic strategies for tau mediated neurodegeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 784-795.	1.9	115

#	ARTICLE	IF	CITATIONS
620	Oxidative stress in Alzheimer's disease: Primary villain or physiological by-product?. Redox Report, 2013, 18, 134-141.	4.5	59
621	Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiology of Aging, 2013, 34, 22-34.	3.1	58
622	Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. NeuroImage: Clinical, 2013, 2, 356-365.	2.7	297
623	Disclosure of amyloid imaging results to research participants: Has the time come?. Alzheimer's and Dementia, 2013, 9, 741.	0.8	37
624	Balancing Survival: The Role of CTGF in Controlling Experience-Modulated Olfactory Circuitry. Neuron, 2013, 79, 1037-1039.	8.1	3
625	R-flurbiprofen improves tau, but not A β pathology in a triple transgenic model of Alzheimer's disease. Brain Research, 2013, 1541, 115-127.	2.2	30
626	Anesthesia and tau pathology. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 47, 147-155.	4.8	88
627	Imaging Tau Deposits In Vivo: Progress in Viewing More of The Proteopathy Picture. Neuron, 2013, 79, 1035-1037.	8.1	13
628	A Cross-Sectional Study on Cerebrospinal Fluid Biomarker Levels in Cognitively Normal Elderly Subjects With or Without a Family History of Alzheimer's Disease. CNS Neuroscience and Therapeutics, 2013, 19, 38-42.	3.9	15
629	Chronic neuropathologies of single and repetitive TBI: substrates of dementia?. Nature Reviews Neurology, 2013, 9, 211-221.	10.1	590
630	From Soluble A β to Progressive A β Aggregation: Could Prion-Like Templated Misfolding Play a Role?. Brain Pathology, 2013, 23, 333-341.	4.1	32
631	White matter abnormalities associated with Alzheimer's disease and mild cognitive impairment: a critical review of MRI studies. Expert Review of Neurotherapeutics, 2013, 13, 483-493.	2.8	68
632	Alzheimer disease. Prion, 2013, 7, 14-19.	1.8	108
633	Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis. Medical Clinics of North America, 2013, 97, 377-398.	2.5	52
634	The amyloid cascade is not the only pathway to AD. Nature Reviews Neurology, 2013, 9, 356-356.	10.1	9
635	Prospective Flutemetamol Positron Emission Tomography and Histopathology in Normal Pressure Hydrocephalus. Neurodegenerative Diseases, 2014, 13, 237-245.	1.4	18
636	Higher Rates of Decline for Women and APOE4 Carriers. American Journal of Neuroradiology, 2013, 34, 2287-2293.	2.4	152
637	Neuroimaging and the Search for a Cure for Alzheimer Disease. Radiology, 2013, 269, 671-691.	7.3	42

#	ARTICLE	IF	CITATIONS
638	Cognitive trajectories associated with β^2 -amyloid deposition in the oldest-old without dementia. <i>Neurology</i> , 2013, 80, 1378-1384.	1.1	77
639	Socioeconomic status as a risk factor for dementia death: individual participant meta-analysis of 86 508 men and women from the UK. <i>British Journal of Psychiatry</i> , 2013, 203, 10-17.	2.8	96
640	Risk Factors for β^2 -Amyloid Deposition in Healthy Aging. <i>JAMA Neurology</i> , 2013, 70, 600.	9.0	216
641	Positron Emission Tomography Applications in Clinical Neurology. <i>Seminars in Neurology</i> , 2013, 32, 421-431.	1.4	22
642	Trimeric Tau Is Toxic to Human Neuronal Cells at Low Nanomolar Concentrations. <i>International Journal of Cell Biology</i> , 2013, 2013, 1-9.	2.5	70
643	Experimental Evidence of ω -3 Polyunsaturated Fatty Acid Modulation of Inflammatory Cytokines and Bioactive Lipid Mediators: Their Potential Role in Inflammatory, Neurodegenerative, and Neoplastic Diseases. <i>BioMed Research International</i> , 2013, 2013, 1-13.	1.9	64
644	Age and apolipoprotein E ϵ 4 effects on neural correlates of odor memory.. <i>Behavioral Neuroscience</i> , 2013, 127, 339-349.	1.2	11
645	Shared Vulnerability of Two Synaptically-Connected Medial Temporal Lobe Areas to Age and Cognitive Decline: A Seven Tesla Magnetic Resonance Imaging Study. <i>Journal of Neuroscience</i> , 2013, 33, 16666-16672.	3.6	41
646	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. <i>Neurology</i> , 2013, 81, 1732-1740.	1.1	182
647	Amyloid Beta Peptides Differentially Affect Hippocampal Theta Rhythms <i>In Vitro</i> . <i>International Journal of Peptides</i> , 2013, 2013, 1-11.	0.7	19
648	Time to diagnosis in young-onset dementia as compared with late-onset dementia. <i>Psychological Medicine</i> , 2013, 43, 423-432.	4.5	190
649	In vivo parahippocampal white matter pathology as a biomarker of disease progression to Alzheimer's disease. <i>Journal of Comparative Neurology</i> , 2013, 521, 4300-4317.	1.6	27
650	Positron emission tomography with [¹⁸ F]flutemetamol and [¹¹ C]PiB for <i>in vivo</i> detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. <i>European Journal of Neurology</i> , 2013, 20, 1043-1052.	3.3	40
651	Education level predicts retrospective metamemory accuracy in healthy aging and Alzheimer's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 971-982.	1.3	14
652	Serum Multivalent Cationic Pattern: Speculation on the Efficient Approach for Detection of Alzheimer's Disease. <i>Scientific Reports</i> , 2013, 3, 2782.	3.3	16
653	A Novel Drug Candidate for Alzheimer's Disease Treatment: gx-50 Derived from Zanthoxylum Bungeanum. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 203-213.	2.6	52
654	Examining the cognitive effects of a special extract of Bacopa monniera (CDRI08: Keenmnd): A review of ten years of research at Swinburne University. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 254.	2.1	21
655	Regional Amyloid Deposition in Amnesic Mild Cognitive Impairment and Alzheimer's Disease Evaluated by [¹⁸ F]AV-45 Positron Emission Tomography in Chinese Population. <i>PLoS ONE</i> , 2013, 8, e58974.	2.5	44

#	ARTICLE	IF	CITATIONS
656	P-Glycoprotein Altered Expression in Alzheimer's Disease: Regional Anatomic Variability. Journal of Neurodegenerative Diseases, 2013, 2013, 1-7.	1.1	8
657	Human Pluripotent Stem Cells Modeling Neurodegenerative Diseases. , 2013, , .		2
658	Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer's Disease and Mild Cognitive Impairment. Advances in Geriatrics, 2014, 2014, 1-15.	1.6	2
659	CSF Biomarkers of Alzheimer's Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. Advances in Geriatrics, 2014, 2014, 1-14.	1.6	15
660	Dad Can Do Time Travel - But Grandpa Can't!. Frontiers for Young Minds, 2014, 2, .	0.8	1
661	Insulin dysfunction and Tau pathology. Frontiers in Cellular Neuroscience, 2014, 8, 22.	3.7	95
662	Interleukin-18 alters protein expressions of neurodegenerative diseases-linked proteins in human SH-SY5Y neuron-like cells. Frontiers in Cellular Neuroscience, 2014, 8, 214.	3.7	22
663	Neuronal Inclusions. , 2014, , 441-455.		1
664	The role of tau protein in HIV-associated neurocognitive disorders. Molecular Neurodegeneration, 2014, 9, 40.	10.8	24
665	Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology, 2014, 83, 1753-1760.	1.1	181
667	Verbal Comprehension Ability in Aphasia: Demographic and Lexical Knowledge Effects. Behavioural Neurology, 2014, 2014, 1-8.	2.1	15
668	Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD. Neurology, 2014, 82, 752-760.	1.1	44
669	Variations of white matter tract length in regions of emotional regulation as assessed in alzheimer diffusion tensor images. , 2014, , .		1
670	Amyloid deposition is decreasing in aging brains. Neurology, 2014, 82, 326-331.	1.1	38
671	Regional Neuronal Network Failure and Cognition in Late-Onset Sporadic Alzheimer Disease. American Journal of Neuroradiology, 2014, 35, S18-S30.	2.4	13
672	Tracking the earliest pathologic changes in Alzheimer disease. Neurology, 2014, 82, 1576-1577.	1.1	19
673	Serum levels of albumin-amyloid beta complexes are decreased in Alzheimer's disease. Geriatrics and Gerontology International, 2014, 14, 716-723.	1.5	40
674	Do the Cambridge Neuropsychological Test Automated Battery episodic memory measures discriminate amnesic mild cognitive impairment?. International Journal of Geriatric Psychiatry, 2014, 29, 602-609.	2.7	25

#	ARTICLE	IF	CITATIONS
675	Tau PET Imaging in Alzheimer's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 500.	4.2	141
676	Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus. <i>PLoS ONE</i> , 2014, 9, e91974.	2.5	91
677	Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease. <i>Science Translational Medicine</i> , 2014, 6, 226ra30.	12.4	320
678	FDG-PET and amyloid-PET imaging. <i>Current Opinion in Neurology</i> , 2014, 27, 405-413.	3.6	55
679	Alzheimer Disease and Cellular Mechanisms of Memory Storage. <i>Journal of Neuropathology and Experimental Neurology</i> , 2014, 73, 192-205.	1.7	17
680	Effects of Naproxen on Immune Responses in a Colchicine-Induced Rat Model of Alzheimer's Disease. <i>NeuroImmunoModulation</i> , 2014, 21, 304-321.	1.8	22
681	Developments in Tau PET Imaging. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 547-553.	0.5	45
682	Eye Blink Rate as a biological marker of Mild Cognitive Impairment. <i>International Journal of Psychophysiology</i> , 2014, 93, 12-16.	1.0	40
683	Effects of ginseng k-g3, an Rg3-enriched fraction, on scopolamine-induced memory impairment and learning deficit in mice. <i>Journal of Ginseng Research</i> , 2014, 38, 1-7.	5.7	26
684	Genetic modification of the relationship between phosphorylated tau and neurodegeneration. <i>Alzheimer's and Dementia</i> , 2014, 10, 637.	0.8	21
685	The neuropsychology of normal aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 84-92.	0.8	55
686	What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. <i>Progress in Neurobiology</i> , 2014, 117, 20-40.	5.7	608
687	Understanding the cause of sporadic Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 621-630.	2.8	47
688	Cerebrospinal fluid A β -amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2014, 76, 223-230.	5.3	110
689	Aging, cortical injury and Alzheimer's disease-like pathology in the guinea pig brain. <i>Neurobiology of Aging</i> , 2014, 35, 1345-1351.	3.1	23
690	A Focus on Structural Brain Imaging in the Alzheimer's Disease Neuroimaging Initiative. <i>Biological Psychiatry</i> , 2014, 75, 527-533.	1.3	35
691	Tau-aggregation inhibitor therapy for Alzheimer's disease. <i>Biochemical Pharmacology</i> , 2014, 88, 529-539.	4.4	221
692	Cholinesterase inhibitors should not be prescribed for mild cognitive impairment. <i>Evidence-Based Medicine</i> , 2014, 19, 101-101.	0.6	17

#	ARTICLE	IF	CITATIONS
693	Regional analysis of striatal and cortical amyloid deposition in patients with ^A Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2014, 40, 2701-2706.	2.6	26
694	What is the role of neuroimaging in dementia? A review. <i>Imaging</i> , 2014, 23, 20120015.	0.0	0
695	Enhancement of Binding Affinity for Amyloid Aggregates by Multivalent Interactions of ^{99m}Tc-Hydroxamamide Complexes. <i>Molecular Pharmaceutics</i> , 2014, 11, 1132-1139.	4.6	23
696	Imaging Frontotemporal Lobar Degeneration. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 489.	4.2	41
697	Age-specific population frequencies of cerebral β^2 -amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2014, 13, 997-1005.	10.2	297
698	The Relevance of Beta-Amyloid on Markers of Alzheimer's Disease in Clinically Normal Individuals and Factors That Influence These Associations. <i>Neuropsychology Review</i> , 2014, 24, 300-312.	4.9	34
699	Heat shock proteins in neurodegenerative disorders and aging. <i>Journal of Cell Communication and Signaling</i> , 2014, 8, 293-310.	3.4	145
700	Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 714-722.	6.4	95
701	Diagnostic effectiveness of quantitative [18F]flutemetamol PET imaging for detection of fibrillar amyloid β^2 using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. <i>Acta Neuropathologica Communications</i> , 2014, 2, 46.	5.2	19
703	Herpes virus in Alzheimer's disease: relation to progression of the disease. <i>Neurobiology of Aging</i> , 2014, 35, 122-129.	3.1	148
704	Chronic Aluminum Intake Causes Alzheimer's Disease: Applying Sir Austin Bradford Hill's Causality Criteria. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 765-838.	2.6	97
706	At the crossroads of preclinical AD and normal brain ageing. <i>Lancet Neurology</i> , The, 2014, 13, 965-966.	10.2	3
707	Diffusion tensor imaging of white matter degeneration in Alzheimer's disease and mild cognitive impairment. <i>Neuroscience</i> , 2014, 276, 206-215.	2.3	183
708	Attractiveness and consumption of finger foods in elderly Alzheimer's disease patients. <i>Food Quality and Preference</i> , 2014, 34, 62-69.	4.6	26
709	Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 482-491.	3.1	94
710	Ageing and apoE change DHA homeostasis: relevance to age-related cognitive decline. <i>Proceedings of the Nutrition Society</i> , 2014, 73, 80-86.	1.0	34
711	Rates of β^2 -amyloid accumulation are independent of hippocampal neurodegeneration. <i>Neurology</i> , 2014, 82, 1605-1612.	1.1	119
712	Alzheimer's disease or ^A Alzheimer's syndrome?: a longitudinal computed tomography neuroradiological follow-up study of 56 cases diagnosed clinically as ^A Alzheimer's disease. <i>Psychogeriatrics</i> , 2015, 15, 255-271.	1.2	2

#	ARTICLE	IF	CITATIONS
713	Alzheimer's disease. Nature Reviews Disease Primers, 2015, 1, 15056.	30.5	1,210
714	Impaired Parahippocampus Connectivity in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 49, 1051-1064.	2.6	50
715	Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. Journal of Alzheimer's Disease, 2015, 49, 733-741.	2.6	18
716	Myelin Basic Protein Associates with A β PP, A β 1-42, and Amyloid Plaques in Cortex of Alzheimer's Disease Brain. Journal of Alzheimer's Disease, 2015, 44, 1213-1229.	2.6	67
717	Leukocyte Telomere Length in Alzheimer's Disease Patients with a Different Rate of Progression. Journal of Alzheimer's Disease, 2015, 46, 761-769.	2.6	32
718	Inflammation Combined with Ischemia Produces Myelin Injury and Plaque-Like Aggregates of Myelin, Amyloid- β and A β PP in Adult Rat Brain. Journal of Alzheimer's Disease, 2015, 46, 507-523.	2.6	36
719	Alzheimer's Disease, Neural Basis of. , 2015, , 591-596.		2
720	Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. Frontiers in Neurology, 2015, 6, 142.	2.4	25
721	Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. Frontiers in Neurology, 2015, 6, 256.	2.4	16
722	Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging. Frontiers in Neuroscience, 2015, 9, 482.	2.8	26
723	Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Current Alzheimer Research, 2015, 12, 712-722.	1.4	134
724	Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-Ethnic Population. PLoS ONE, 2015, 10, e0123743.	2.5	33
725	Integrating Retrogenesis Theory to Alzheimer's Disease Pathology: Insight from DTI-TBSS Investigation of the White Matter Microstructural Integrity. BioMed Research International, 2015, 2015, 1-11.	1.9	55
726	<i>Bacopa monnieri</i> as an Antioxidant Therapy to Reduce Oxidative Stress in the Aging Brain. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-9.	1.2	54
727	S100B Inhibitor Pentamidine Attenuates Reactive Gliosis and Reduces Neuronal Loss in a Mouse Model of Alzheimer's Disease. BioMed Research International, 2015, 2015, 1-11.	1.9	68
728	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 412-419.	2.4	80
729	Combination of dynamic 11C-PIB PET and structural MRI improves diagnosis of Alzheimer's disease. Psychiatry Research - Neuroimaging, 2015, 233, 131-140.	1.8	12
730	Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. Journal of Medicinal Chemistry, 2015, 58, 4365-4382.	6.4	88

#	ARTICLE	IF	CITATIONS
731	Commentary: is Alzheimer's disease uniquely human?. <i>Neurobiology of Aging</i> , 2015, 36, 553-555.	3.1	55
732	Co-morbid beta-amyloid toxicity and stroke produce impairments in an ambiguous context task in rats without any impairment in spatial working memory. <i>Neurobiology of Learning and Memory</i> , 2015, 119, 42-51.	1.9	4
733	High membrane protein oxidation in the human cerebral cortex. <i>Redox Biology</i> , 2015, 4, 200-207.	9.0	32
734	Truncation and activation of GSK-3 β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease. <i>Scientific Reports</i> , 2015, 5, 8187.	3.3	75
735	Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. <i>Journal of Neural Transmission</i> , 2015, 122, 607-617.	2.8	79
736	Biomarkers of Alzheimer's disease and mild cognitive impairment: A current perspective. <i>Advances in Medical Sciences</i> , 2015, 60, 76-82.	2.1	56
737	Pulmonary function as a risk factor for dementia death: an individual participant meta-analysis of six UK general population cohort studies. <i>Journal of Epidemiology and Community Health</i> , 2015, 69, 550-556.	3.7	34
738	What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?. <i>Lancet Psychiatry</i> , 2015, 2, 756-764.	7.4	16
739	Lipidomics of Human Brain Aging and Alzheimer's Disease Pathology. <i>International Review of Neurobiology</i> , 2015, 122, 133-189.	2.0	139
740	Luteinizing hormone as a key player in the cognitive decline of Alzheimer's disease. <i>Hormones and Behavior</i> , 2015, 76, 48-56.	2.1	26
741	A Selective Prostaglandin E ₂ Receptor Subtype 2 (EP2) Antagonist Increases the Macrophage-Mediated Clearance of Amyloid-Beta Plaques. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5256-5273.	6.4	45
742	[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1052-1061.	6.4	117
743	Awareness of Memory Ability and Change: (In)Accuracy of Memory Self-Assessments in Relation to Performance. <i>Journal of Population Ageing</i> , 2015, 8, 71-99.	1.4	25
744	Midlife mental distress and risk for dementia up to 27 years later: the Nord-Trøndelag Health Study (HUNT) in linkage with a dementia registry in Norway. <i>BMC Geriatrics</i> , 2015, 15, 23.	2.7	27
745	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , 2015, 138, 761-771.	7.6	222
746	mTor mediates tau localization and secretion: Implication for Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 1646-1657.	4.1	95
747	Acute amnesic encephalopathy in amyloid- β oligomer-injected mice is due to their widespread diffusion in vivo. <i>Neurobiology of Aging</i> , 2015, 36, 2043-2052.	3.1	23
748	Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 699.	9.0	75

#	ARTICLE	IF	CITATIONS
749	Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2015, 74, 319-344.	1.7	105
750	Functional correlates of t-Tau, p-Tau and A β 42 amyloid cerebrospinal fluid levels in Alzheimer's disease. Nuclear Medicine Communications, 2015, 36, 461-468.	1.1	22
751	Tau Assembly: The Dominant Role of PHF6 (VQIVYK) in Microtubule Binding Region Repeat R3. Journal of Physical Chemistry B, 2015, 119, 4582-4593.	2.6	134
752	Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. NeuroImage, 2015, 113, 61-69.	4.2	38
753	Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults. Neuropsychologia, 2015, 78, 63-72.	1.6	35
754	Different cerebrospinal fluid levels of A β 42 between general paresis and asymptomatic neurosyphilis. European Journal of Neurology, 2015, 22, 853-858.	3.3	8
755	Neuropathologic correlates of regional brain volumes in a community cohort of older adults. Neurobiology of Aging, 2015, 36, 2798-2805.	3.1	38
756	The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain, 2015, 138, 2814-2833.	7.6	380
757	Occupational Complexity and Cognitive Reserve in a Middle-Aged Cohort at Risk for Alzheimer's Disease. Archives of Clinical Neuropsychology, 2015, 30, 634-642.	0.5	96
758	Evidence for human transmission of amyloid- β 2 pathology and cerebral amyloid angiopathy. Nature, 2015, 525, 247-250.	27.8	418
759	Neuroanatomy and Pathology of Sporadic Alzheimer's Disease. Advances in Anatomy, Embryology and Cell Biology, 2015, , .	1.6	81
760	Periodontal disease associates with higher brain amyloid load in normal elderly. Neurobiology of Aging, 2015, 36, 627-633.	3.1	198
761	Tau imaging: early progress and future directions. Lancet Neurology, The, 2015, 14, 114-124.	10.2	432
762	Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer's disease. International Journal of Neuroscience, 2015, 125, 747-754.	1.6	20
763	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 58-69.	0.8	352
764	At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 70-98.	0.8	420
765	The Neuroprotective Properties of the Amyloid Precursor Protein Following Traumatic Brain Injury. , 2016, 7, 163.		84
766	Lyme Disease: A Bioethical Morass. Journal of Clinical Research & Bioethics, 2016, 07, .	0.2	2

#	ARTICLE	IF	CITATIONS
767	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. BioMed Research International, 2016, 2016, 1-15.	1.9	138
768	Alzheimer's Disease: From Animal Models to the Human Syndrome. , 0, , .		1
769	The Role of the Carboxyl-Terminal Sequence of Tau and MAP2 in the Pathogenesis of Dementia. Frontiers in Molecular Neuroscience, 2016, 9, 158.	2.9	16
770	Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer's Disease Phenotypes. PLoS ONE, 2016, 11, e0161969.	2.5	405
771	The Relationship Between Mobility Dysfunction Staging and Global Cognitive Performance. Alzheimer Disease and Associated Disorders, 2016, 30, 230-236.	1.3	26
772	Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies. Journal of Neurochemistry, 2016, 139, 224-236.	3.9	17
773	Contribution of neuroimaging in the diagnosis of brain disorders: Recent findings and future applications. International Journal of Imaging Systems and Technology, 2016, 26, 124-135.	4.1	3
774	Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. Journal of Neurochemistry, 2016, 138, 54-70.	3.9	252
775	Beer Drinking Associates with Lower Burden of Amyloid Beta Aggregation in the Brain: Helsinki Sudden Death Series. Alcoholism: Clinical and Experimental Research, 2016, 40, 1473-1478.	2.4	18
776	Family member deaths across adulthood predict Alzheimer's disease risk: The Cache County Study. International Journal of Geriatric Psychiatry, 2016, 31, 256-263.	2.7	7
777	Synergistic stress exacerbation in hippocampal neurons: Evidence favoring the dual-hit hypothesis of neurodegeneration. Hippocampus, 2016, 26, 980-994.	1.9	20
778	Higher Prevalence of τ 43 Proteinopathy in Cognitively Normal Asians: A Clinicopathological Study on a Multiethnic Sample. Brain Pathology, 2016, 26, 177-185.	4.1	23
779	Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome. Brain Pathology, 2016, 26, 593-605.	4.1	180
780	First magnetic resonance imaging studies on aluminium maltolate-treated aged New Zealand rabbits: an Alzheimer's animal model. Psychogeriatrics, 2016, 16, 263-267.	1.2	4
782	α 2 microglobulin levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476.	6.9	392
783	Frontal, Striatal, and Medial Temporal Sensitivity to Value Distinguishes Risk-Taking from Risk-Averse Older Adults during Decision Making. Journal of Neuroscience, 2016, 36, 12498-12509.	3.6	22
784	Cortical Implications of Advancing Age and Disease Duration in Parkinson's Disease Patients with Postural Instability and Gait Dysfunction. Journal of Parkinson's Disease, 2016, 6, 441-451.	2.8	18
785	Obesity and age-related alterations in the gene expression of zinc-transporter proteins in the human brain. Translational Psychiatry, 2016, 6, e838-e838.	4.8	32

#	ARTICLE	IF	CITATIONS
786	PET Imaging of Tau Deposition in the Aging Human Brain. <i>Neuron</i> , 2016, 89, 971-982.	8.1	899
787	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. <i>Neurobiology of Aging</i> , 2016, 39, 99-107.	3.1	34
788	Amyloid Imaging in Dementia and Related Disorders. , 2016, , 89-102.		0
789	“New Old Pathologies” AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 482-498.	1.7	130
790	Tau: From research to clinical development. <i>Alzheimer's and Dementia</i> , 2016, 12, 1033-1039.	0.8	117
791	Why Are Humans Vulnerable to Alzheimer’s Disease?. , 2016, , 329-345.		1
792	Serum Levels of Albumin-β ² -Amyloid Complex in Patients with Depression. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 764-772.	1.2	7
793	Curcumin improves tau-induced neuronal dysfunction of nematodes. <i>Neurobiology of Aging</i> , 2016, 39, 69-81.	3.1	43
795	Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 51-62.	2.4	59
796	Discovery of 6-(Fluoro- ¹⁸ F)-3-(1 <i>H</i> -pyrrolo[2,3- <i>c</i>]pyridin-1-yl)isoquinolin-5-amine ([¹⁸ F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4778-4789.	6.4	142
798	Better Utilization of Mouse Models of Neurodegenerative Diseases in Preclinical Studies: From the Bench to the Clinic. <i>Methods in Molecular Biology</i> , 2016, 1438, 311-347.	0.9	3
799	Mouse Models for Drug Discovery. <i>Methods in Molecular Biology</i> , 2016, , .	0.9	5
800	Evolutionary Thinking in Medicine. , 2016, , .		7
801	An International Survey of Brain Banking Operation and Characterization Practices. <i>Biopreservation and Biobanking</i> , 2016, 14, 464-469.	1.0	17
803	Environmental risk factors for dementia: a systematic review. <i>BMC Geriatrics</i> , 2016, 16, 175.	2.7	259
804	Carotenoids and Neurobiological Health. <i>Advances in Neurobiology</i> , 2016, 12, 199-228.	1.8	19
805	Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 38.	6.2	48
806	Evidence for transmissibility of Alzheimer disease pathology: Cause for concern?. <i>Cmaj</i> , 2016, 188, E210-E212.	2.0	3

#	ARTICLE	IF	CITATIONS
807	Untangling tau imaging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 39-42.	2.4	4
808	Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. Immunotherapy, 2016, 8, 1119-1134.	2.0	61
809	Animal Models of Behavior Genetics. , 2016, , .		0
810	Distribution and Load of Amyloid- β Pathology in Parkinson Disease and Dementia with Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2016, 75, 936-945.	1.7	109
811	Tau positron emission tomographic imaging in aging and early Alzheimer disease. Annals of Neurology, 2016, 79, 110-119.	5.3	778
812	A Smart Near-Infrared Fluorescence Probe for Selective Detection of Tau Fibrils in Alzheimer's Disease. ACS Chemical Neuroscience, 2016, 7, 1474-1481.	3.5	40
813	Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. JAMA Neurology, 2016, 73, 1185.	9.0	52
814	Clinical Diagnosis of Alzheimer's Disease. , 2016, , 27-48.		14
815	Collinge et al. reply. Nature, 2016, 535, E2-E3.	27.8	3
816	Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport. Experimental Neurology, 2016, 283, 318-329.	4.1	28
817	Neurodegenerative Diseases and Dementia. , 2016, , 167-197.		0
818	Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology. Journal of Alzheimer's Disease, 2016, 52, 863-873.	2.6	43
819	Tau and tauopathies. Brain Research Bulletin, 2016, 126, 238-292.	3.0	444
820	Synaptopathies: synaptic dysfunction in neurological disorders – A review from students to students. Journal of Neurochemistry, 2016, 138, 785-805.	3.9	244
821	Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology, 2016, 87, 481-488.	1.1	159
822	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β -Amyloid and Tauopathy. JAMA Neurology, 2016, 73, 1070.	9.0	246
823	Drug treatments in Alzheimer's disease. Clinical Medicine, 2016, 16, 247-253.	1.9	344
824	Seeds of neuroendocrine doubt. Nature, 2016, 535, E1-E2.	27.8	8

#	ARTICLE	IF	CITATIONS
825	Gd-nanoparticles functionalization with specific peptides for β -amyloid plaques targeting. Journal of Nanobiotechnology, 2016, 14, 60.	9.1	55
826	Gram-negative bacterial molecules associate with Alzheimer disease pathology. Neurology, 2016, 87, 2324-2332.	1.1	374
827	Imaging of Cerebral Amyloid Angiopathy with Bivalent ^{99m}Tc -Hydroxamamide Complexes. Scientific Reports, 2016, 6, 25990.	3.3	17
828	Post-mortem histopathology underlying ^{12}I -amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathologica Communications, 2016, 4, 130.	5.2	76
829	Is cerebral glucose metabolism related to blood-brain barrier dysfunction and intrathecal IgG synthesis in Alzheimer disease?. Medicine (United States), 2016, 95, e4206.	1.0	18
830	PET Imaging as a Diagnostic Tool in Alzheimer's Disease. Methods in Pharmacology and Toxicology, 2016, , 199-213.	0.2	0
831	Cognitive decline in normal aging and early Alzheimer's disease: A continuous or discontinuous transition? A historical review and future research proposal. Cogent Psychology, 2016, 3, 1185226.	1.3	4
832	Amyloid and Amyloid Fibrils. Springer Theses, 2016, , 1-30.	0.1	0
833	Early detection of Alzheimer's disease using MRI hippocampal texture. Human Brain Mapping, 2016, 37, 1148-1161.	3.6	165
834	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. Seminars in Nuclear Medicine, 2016, 46, 57-87.	4.6	16
835	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.8	1,318
836	Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Neurology, 2016, 86, 1499-1506.	1.1	39
837	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Journal of Neurochemistry, 2016, 139, 290-317.	3.9	58
838	Amyloid imaging: Past, present and future perspectives. Ageing Research Reviews, 2016, 30, 95-106.	10.9	43
839	Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. Neurological Sciences, 2016, 37, 663-672.	1.9	52
840	Neuroimaging biomarkers in Alzheimer's disease and other dementias. Ageing Research Reviews, 2016, 30, 4-16.	10.9	32
841	Local and distributed PiB accumulation associated with development of preclinical Alzheimer's disease. Neurobiology of Aging, 2016, 38, 104-111.	3.1	15
842	Amyloid- β -Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer's Disease. Analytical Chemistry, 2016, 88, 2755-2762.	6.5	97

#	ARTICLE	IF	CITATIONS
843	Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium. Expert Review of Neurotherapeutics, 2016, 16, 259-277.	2.8	35
844	Gait and cognition: Mapping the global and discrete relationships in ageing and neurodegenerative disease. Neuroscience and Biobehavioral Reviews, 2016, 64, 326-345.	6.1	216
845	Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: 18F-florbetapir (AV-45/Amyvid) PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1067-1076.	6.4	31
846	Alzheimer's disease: The amyloid hypothesis on trial. British Journal of Psychiatry, 2016, 208, 1-3.	2.8	112
847	Propagation of A β pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathologica, 2016, 131, 5-25.	7.7	68
848	Tau imaging in neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1139-1150.	6.4	104
849	Repetitive head trauma, chronic traumatic encephalopathy and tau: Challenges in translating from mice to men. Experimental Neurology, 2016, 275, 389-404.	4.1	75
850	Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions. Current Opinion in Neurobiology, 2016, 36, 43-51.	4.2	66
851	Why therapies for Alzheimer's disease do not work: Do we have consensus over the path to follow?. Ageing Research Reviews, 2016, 25, 70-84.	10.9	23
852	Monoaminergic neuropathology in Alzheimer's disease. Progress in Neurobiology, 2017, 151, 101-138.	5.7	206
853	Tau passive immunization inhibits not only tau but also A β pathology. Alzheimer's Research and Therapy, 2017, 9, 1.	6.2	147
854	Tau and β -Amyloid Are Associated with Medial Temporal Lobe Structure, Function, and Memory Encoding in Normal Aging. Journal of Neuroscience, 2017, 37, 3192-3201.	3.6	110
855	Amyloid and tau PET demonstrate region-specific associations in normal older people. NeuroImage, 2017, 150, 191-199.	4.2	67
856	cGMP production of the radiopharmaceutical [¹⁸ F]MK-6240 for PET imaging of human neurofibrillary tangles. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 263-269.	1.0	27
857	Energy and the Alzheimer brain. Neuroscience and Biobehavioral Reviews, 2017, 75, 297-313.	6.1	32
858	Prevention of Amyloid- β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound. Journal of Alzheimer's Disease, 2017, 58, 215-230.	2.6	18
859	Is sporadic Alzheimer's disease a developmental disorder?. Journal of Neurochemistry, 2017, 143, 396-408.	3.9	61
860	Family History of Alzheimer's Disease is Associated with Impaired Perceptual Discrimination of Novel Objects. Journal of Alzheimer's Disease, 2017, 57, 735-745.	2.6	13

#	ARTICLE	IF	CITATIONS
861	Epidemiological Approaches to Understanding the Link Between Type 2 Diabetes and Dementia. Journal of Alzheimer's Disease, 2017, 59, 393-403.	2.6	36
862	Serious Games for Dementia. , 2017, , .		21
863	Multiregional Age-Associated Reduction of Brain Neuronal Reserve Without Association With Neurofibrillary Degeneration or β^2 -Amyloidosis. Journal of Neuropathology and Experimental Neurology, 2017, 76, 439-457.	1.7	14
864	Journeys to Engagement. , 2017, , .		4
865	Lower Visual Avoidance in Dementia Patients Is Associated with Greater Psychological Distress in Caregivers. Dementia and Geriatric Cognitive Disorders, 2017, 43, 247-258.	1.5	17
866	Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition. Journal of Alzheimer's Disease, 2017, 58, 829-840.	2.6	31
867	Sensory Impairments and Cognitive Function in Middle-Aged Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 1087-1090.	3.6	52
868	Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. Annals of Neurology, 2017, 81, 871-882.	5.3	51
869	The association between tau PET and retrospective cortical thinning in clinically normal elderly. NeuroImage, 2017, 157, 612-622.	4.2	74
870	Linking Amyloid- β^2 and Tau Deposition in Alzheimer Disease. JAMA Neurology, 2017, 74, 766.	9.0	10
871	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA - Journal of the American Medical Association, 2017, 317, 2305.	7.4	311
872	The expression and activity of K V 3.4 channel subunits are precociously upregulated in astrocytes exposed to $A\beta^2$ oligomers and in astrocytes of Alzheimer's disease Tg2576 mice. Neurobiology of Aging, 2017, 54, 187-198.	3.1	33
873	Amyloidosis and neurodegeneration result in distinct structural connectivity patterns in mild cognitive impairment. Neurobiology of Aging, 2017, 55, 177-189.	3.1	20
874	Association between tau deposition and antecedent amyloid- β^2 accumulation rates in normal and early symptomatic individuals. Brain, 2017, 140, 1499-1512.	7.6	93
875	Insulin Resistance Predicts Cognitive Decline: An 11-Year Follow-up of a Nationally Representative Adult Population Sample. Diabetes Care, 2017, 40, 751-758.	8.6	95
876	Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2017, 974, 21-48.	1.6	25
877	Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 21-30.	2.4	86
878	Inter-rater variability of visual interpretation and comparison with quantitative evaluation of ^{11}C -PiB PET amyloid images of the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multicenter study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 850-857.	6.4	90

#	ARTICLE	IF	CITATIONS
879	Imaging Biomarkers in Alzheimer's Disease: A Practical Guide for Clinicians. Journal of Alzheimer's Disease Reports, 2017, 1, 71-88.	2.2	18
880	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	2.4	162
881	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1119-1128.	2.6	27
882	Up-regulation of casein kinase 1 μ is involved in tau pathogenesis in Alzheimer's disease. Scientific Reports, 2017, 7, 13478.	3.3	21
883	Individual differences in associative memory among older adults explained by hippocampal subfield structure and function. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12075-12080.	7.1	62
884	A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?. Neurology and Therapy, 2017, 6, 5-13.	3.2	34
885	Multivariate analyses of peripheral blood leukocyte transcripts distinguish Alzheimer's, Parkinson's, control, and those at risk for developing Alzheimer's. Neurobiology of Aging, 2017, 58, 225-237.	3.1	15
886	Tau-imaging in neurodegeneration. Methods, 2017, 130, 114-123.	3.8	34
887	Increased florbetapir binding in the temporal neocortex from age 20 to 60 years. Neurology, 2017, 89, 2438-2446.	1.1	38
888	Analysis of structural connectivity on progression of Alzheimer's disease using diffusion tensor imaging. , 2017, , .		2
889	General Practice Clinical Data Help Identify Dementia Hotspots: A Novel Geospatial Analysis Approach. Journal of Alzheimer's Disease, 2017, 61, 125-134.	2.6	18
890	Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia. Current Treatment Options in Neurology, 2017, 19, 46.	1.8	20
891	Andrographolide attenuates microglia-mediated A β neurotoxicity partially through inhibiting NF- κ B and JNK MAPK signaling pathway. Immunopharmacology and Immunotoxicology, 2017, 39, 276-284.	2.4	46
892	Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurology, 2017, 17, 75.	1.8	64
893	A β -amyloid and Tau Imaging in Dementia. Seminars in Nuclear Medicine, 2017, 47, 75-88.	4.6	96
894	Molecular Imaging and Precision Medicine in Dementia and Movement Disorders. PET Clinics, 2017, 12, 119-136.	3.0	1
895	Epigenetic dysregulation of brainstem nuclei in the pathogenesis of Alzheimer's disease: looking in the correct place at the right time?. Cellular and Molecular Life Sciences, 2017, 74, 509-523.	5.4	14
896	Linear combinations of multiple outcome measures to improve the power of efficacy analysis – Application to clinical trials on early-stage Alzheimer's disease. Biostatistics and Epidemiology, 2017, 1, 36-58.	0.4	5

#	ARTICLE	IF	CITATIONS
897	COMBINING GEOSPATIAL ANALYSIS WITH DEMENTIA RISK UTILISING GENERAL PRACTICE DATA: A SYSTEMATIC REVIEW. <i>Journal of prevention of Alzheimer's disease</i> , The, 2017, 5, 1-7.	2.7	2
898	Of Energy and Entropy: The Ineluctable Impact of Aging in Old Age Dementia. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2672.	4.1	28
899	Old Maids: Aging and Its Impact on Microglia Function. <i>International Journal of Molecular Sciences</i> , 2017, 18, 769.	4.1	163
900	White Matter Deterioration May Foreshadow Impairment of Emotional Valence Determination in Early-Stage Dementia of the Alzheimer Type. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 37.	3.4	4
901	Amyloid Associated Intermittent Network Disruptions in Cognitively Intact Older Subjects: Structural Connectivity Matters. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 418.	3.4	10
902	Regional Cerebral Blood Flow in Mild Cognitive Impairment and Alzheimer's Disease Measured with Arterial Spin Labeling Magnetic Resonance Imaging. <i>International Journal of Alzheimer's Disease</i> , 2017, 2017, 1-10.	2.0	45
903	Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry. <i>Journal of Ophthalmology</i> , 2017, 2017, 1-8.	1.3	29
904	Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients. <i>BMC Geriatrics</i> , 2017, 17, 210.	2.7	9
905	No added diagnostic value of non-phosphorylated tau fraction (p-tau _{rel}) in CSF as a biomarker for differential dementia diagnosis. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 49.	6.2	11
906	Vascular and Subcortical Dementia. <i>Journal of Vascular Medicine & Surgery</i> , 2017, 05, .	0.1	0
907	Regional Differences in Amyloid Deposition between 11C-Pib PET Positive Patients with and without Elevated Striatal Amyloid Uptake. , 2017, 07, .		3
908	A Case Report of a 37-Year-Old Alzheimer's Disease Patient with Prominent Striatum Amyloid Retention. <i>Psychiatry Investigation</i> , 2017, 14, 521.	1.6	6
909	Age-related functional changes in domain-specific medial temporal lobe pathways. <i>Neurobiology of Aging</i> , 2018, 65, 86-97.	3.1	118
910	Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation. <i>Neurology</i> , 2018, 90, e1150-e1157.	1.1	53
911	Biomarkers for Preclinical Alzheimer's Disease. <i>Neuromethods</i> , 2018, , .	0.3	5
912	Age-accelerated cognitive decline in asymptomatic adults with CSF β -amyloid. <i>Neurology</i> , 2018, 90, e1306-e1315.	1.1	42
913	Recent developments with tau-based drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 399-410.	5.0	35
914	Subthreshold Amyloid Predicts Tau Deposition in Aging. <i>Journal of Neuroscience</i> , 2018, 38, 4482-4489.	3.6	101

#	ARTICLE	IF	CITATIONS
915	Amyloid Deposits and Idiopathic Normal-Pressure Hydrocephalus: An 18F-Florbetaben Study. <i>European Neurology</i> , 2018, 79, 192-199.	1.4	5
916	Peripheral Retinal Imaging Biomarkers for Alzheimer's Disease: A Pilot Study. <i>Ophthalmic Research</i> , 2018, 59, 182-192.	1.9	64
917	NIA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.8	5,861
918	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 210-216.	2.4	19
919	Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. <i>Nature Neuroscience</i> , 2018, 21, 424-431.	14.8	198
920	Hypoxia-Induced Signaling Activation in Neurodegenerative Diseases: Targets for New Therapeutic Strategies. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 15-38.	2.6	41
921	Imaging tau and amyloid- β^2 proteinopathies in Alzheimer disease and other conditions. <i>Nature Reviews Neurology</i> , 2018, 14, 225-236.	10.1	321
922	Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 246-259.	1.7	31
923	Comparison of odor identification among amnesic and non-amnesic mild cognitive impairment, subjective cognitive decline, and early Alzheimer's dementia. <i>Neurological Sciences</i> , 2018, 39, 557-564.	1.9	28
924	Quantitative MRI Brain Studies in Mild Cognitive Impairment and Alzheimer's Disease: A Methodological Review. <i>IEEE Reviews in Biomedical Engineering</i> , 2018, 11, 97-111.	18.0	80
925	Secreted amyloid precursor protein alpha activates neuronal insulin receptors and prevents diabetes-induced encephalopathy. <i>Experimental Neurology</i> , 2018, 303, 29-37.	4.1	10
926	Ensemble support vector machine classification of dementia using structural MRI and mini-mental state examination. <i>Journal of Neuroscience Methods</i> , 2018, 302, 66-74.	2.5	60
927	La maladie d'Alzheimer, une création nosographique à une logique de prévention. <i>Evolution Psychiatrique</i> , 2018, 83, 313-331.	0.2	3
928	Integrating new findings and examining clinical applications of pattern separation. <i>Nature Neuroscience</i> , 2018, 21, 163-173.	14.8	135
929	BACE1 inhibition more effectively suppresses initiation than progression of β^2 -amyloid pathology. <i>Acta Neuropathologica</i> , 2018, 135, 695-710.	7.7	64
930	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , 2018, 141, 271-287.	7.6	218
931	Network connectivity determines cortical thinning in early Parkinson's disease progression. <i>Nature Communications</i> , 2018, 9, 12.	12.8	198
932	Elevated Markers of Inflammation Are Associated With Longitudinal Changes in Brain Function in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 770-778.	3.6	55

#	ARTICLE	IF	CITATIONS
933	The interactions of p53 with tau and A β as potential therapeutic targets for Alzheimer's disease. <i>Progress in Neurobiology</i> , 2018, 168, 104-127.	5.7	74
934	Alzheimer disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 325-337.	1.8	87
935	Dissociable influences of APOE ϵ 4 and polygenic risk of AD dementia on amyloid and cognition. <i>Neurology</i> , 2018, 90, e1605-e1612.	1.1	71
936	Longitudinal tau PET in ageing and Alzheimer's disease. <i>Brain</i> , 2018, 141, 1517-1528.	7.6	309
937	Glucagon like peptide-1 (GLP-1) links Alzheimer's disease. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018, 12, 469-475.	3.6	58
938	Molecular mechanisms of membrane-associated amyloid aggregation: Computational perspective and challenges. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2018, 1860, 1889-1905.	2.6	40
939	Quantitative sodium MR imaging: A review of its evolving role in medicine. <i>NeuroImage</i> , 2018, 168, 250-268.	4.2	78
940	The cerebellum in Alzheimer's disease: evaluating its role in cognitive decline. <i>Brain</i> , 2018, 141, 37-47.	7.6	222
941	Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years. <i>Alzheimer's and Dementia</i> , 2018, 14, 62-70.	0.8	50
942	Neurodegenerative Dementias After Traumatic Brain Injury. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2018, 30, 7-13.	1.8	36
943	Selective Tau Imaging: Der Stand der Dinge. <i>Journal of Nuclear Medicine</i> , 2018, 59, 175-176.	5.0	17
944	Geriatric Traumatic Brain Injury: Epidemiology, Outcomes, Knowledge Gaps, and Future Directions. <i>Journal of Neurotrauma</i> , 2018, 35, 889-906.	3.4	269
945	Associations Between Tau, β -Amyloid, and Cognition in Parkinson Disease. <i>JAMA Neurology</i> , 2018, 75, 227.	9.0	57
946	Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging. <i>Journal of Neuroscience</i> , 2018, 38, 530-543.	3.6	201
947	Neuropathology of iatrogenic Creutzfeldt-Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of A β pathology. <i>Acta Neuropathologica</i> , 2018, 135, 201-212.	7.7	71
948	Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. <i>JAMA Neurology</i> , 2018, 75, 88.	9.0	33
949	Imaging microglial activation and amyloid burden in amnesic mild cognitive impairment. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1885-1895.	4.3	29
950	Prevalence of transactive response DNA-binding protein 43 (TDP43) proteinopathy in cognitively normal older adults: systematic review and meta-analysis. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 286-297.	3.2	25

#	ARTICLE	IF	CITATIONS
951	Investigating Multimodal Diagnostic Eye Biomarkers of Cognitive Impairment by Measuring Vascular and Neurogenic Changes in the Retina. <i>Frontiers in Physiology</i> , 2018, 9, 1721.	2.8	44
952	Classification of Dementia Based on Over-Sampling Approach and Decision Tree. , 2018, , .		2
953	4 .Risikofaktoren und Prävention. , 2018, , 123-156.		0
954	Microglial activation occurs late during preclinical Alzheimer's disease. <i>Glia</i> , 2018, 66, 2550-2562.	4.9	61
955	Imaging and Molecular Mechanisms of Alzheimer's Disease: A Review. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3702.	4.1	45
956	Toxic Protein Spread in Neurodegeneration: Reality versus Fantasy. <i>Trends in Molecular Medicine</i> , 2018, 24, 1007-1020.	6.7	26
957	Alzheimer's Disease, Visual Search, and Instrumental Activities of Daily Living: A Review and a New Perspective on Attention and Eye Movements. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 901-925.	2.6	11
958	Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease –conformist, nonconformist, and realistic prospects for AD pathogenesis. <i>Translational Neurodegeneration</i> , 2018, 7, 34.	8.0	77
959	The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. <i>Annals of Neurology</i> , 2019, 85, 181-193.	5.3	171
960	Anandamide Effects in a Streptozotocin-Induced Alzheimer's Disease-Like Sporadic Dementia in Rats. <i>Frontiers in Neuroscience</i> , 2018, 12, 653.	2.8	44
961	Association of deposition of tau and amyloid-beta proteins with structural connectivity changes in cognitively normal older adults and Alzheimer's disease spectrum patients. <i>Brain and Behavior</i> , 2018, 8, e01145.	2.2	18
962	Alzheimer's Disease Biomarkers Have Distinct Associations with Specific Hippocampal Subfield Volumes. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 811-823.	2.6	6
963	Healthy Aging and Dementia: Two Roads Diverging in Midlife?. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 275.	3.4	78
964	Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 115-126.	2.6	133
965	Disease-related patterns of in vivo pathology in Corticobasal syndrome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2413-2425.	6.4	26
966	Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S633-S646.	2.6	52
967	Hippocampal and entorhinal cortex volume changes in Alzheimer's disease patients and mild cognitive impairment subjects. , 2018, , .		1
968	Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. <i>Annual Review of Cell and Developmental Biology</i> , 2018, 34, 545-568.	9.4	99

#	ARTICLE	IF	CITATIONS
969	Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. <i>Acta Neuropathologica Communications</i> , 2018, 6, 64.	5.2	36
970	The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2018, 9, 672.	4.8	99
971	Supervoxels-Based Histone as a New Alzheimer's Disease Imaging Biomarker. <i>Sensors</i> , 2018, 18, 1752.	3.8	16
972	Molecular imaging in dementia: Past, present, and future. <i>Alzheimer's and Dementia</i> , 2018, 14, 1522-1552.	0.8	68
973	β -Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 814-826.	1.7	46
974	Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3xTg-AD mice. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 13.	6.2	73
975	Soluble A β 1-42 suppresses TNF- α and activates NLRP3 inflammasome in THP-1 macrophages. <i>Cytokine</i> , 2018, 111, 84-87.	3.2	5
976	Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease (Review). <i>Molecular Medicine Reports</i> , 2018, 18, 639-655.	2.4	15
977	SPECT and PET imaging in Alzheimer's disease. <i>Annals of Nuclear Medicine</i> , 2018, 32, 583-593.	2.2	106
978	Loss of Trem2 in microglia leads to widespread disruption of cell coexpression networks in mouse brain. <i>Neurobiology of Aging</i> , 2018, 69, 151-166.	3.1	25
979	Update on biomarkers for amyloid pathology in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2018, 12, 799-812.	1.4	59
980	Tau-targeting therapies for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2018, 14, 399-415.	10.1	748
981	Oral Dysbiosis and Periodontal Disease: Effects on Systemic Physiology and in Metabolic Diseases, and Effects of Various Therapeutic Strategies. , 2018, , 421-461.		0
982	Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease. <i>Frontiers in Computational Neuroscience</i> , 2019, 13, 54.	2.1	83
983	The neuropathological diagnosis of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2019, 14, 32.	10.8	1,497
984	Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. <i>Journal of Neuroscience</i> , 2019, 39, 7428-7437.	3.6	19
985	APOE ϵ 4 Gene Dose and Sex Effects on Alzheimer's Disease MRI Biomarkers in Older Adults with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 647-658.	2.6	22
986	Identification of Retinal Biomarkers in Alzheimer's Disease Using Optical Coherence Tomography: Recent Insights, Challenges, and Opportunities. <i>Journal of Clinical Medicine</i> , 2019, 8, 996.	2.4	36

#	ARTICLE	IF	CITATIONS
987	Investigation of the Effects of Biochemical Parameters on Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 464-468.	1.9	6
988	Tau Aggregation Correlates with Amyloid Deposition in Both Mild Cognitive Impairment and Alzheimer's Disease Subjects. Journal of Alzheimer's Disease, 2019, 70, 455-465.	2.6	6
989	An one-pot two-step automated synthesis of [18F]T807 injection, its biodistribution in mice and monkeys, and a preliminary study in humans. PLoS ONE, 2019, 14, e0217384.	2.5	3
990	An artificial neural network model for clinical score prediction in Alzheimer disease using structural neuroimaging measures. Journal of Psychiatry and Neuroscience, 2019, 44, 246-250.	2.4	35
991	Diffusion tensor imaging reveals abnormal brain networks in elderly subjects with subjective cognitive deficits. Neurological Sciences, 2019, 40, 2333-2342.	1.9	16
992	Canine Cognitive Dysfunction and Alzheimer's Disease "Two Facets of the Same Disease?". Frontiers in Neuroscience, 2019, 13, 604.	2.8	56
993	Novel Target Selection for Nuclear Medicine Studies. Seminars in Nuclear Medicine, 2019, 49, 357-368.	4.6	12
994	From molecules to system failure: translational frontiers of multimodal imaging in neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2816-2818.	6.4	0
995	Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2019, 12, 271.	2.9	26
996	Detection of early-stage Alzheimer's pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients. PLoS ONE, 2019, 14, e0225178.	2.5	12
997	What are the threats to successful brain and cognitive aging?. Neurobiology of Aging, 2019, 83, 130-134.	3.1	20
998	AD molecular: Imaging tau aggregates with positron emissions tomography. Progress in Molecular Biology and Translational Science, 2019, 165, 107-138.	1.7	10
999	A β 2 Seeding as a Tool to Study Cerebral Amyloidosis and Associated Pathology. Frontiers in Molecular Neuroscience, 2019, 12, 233.	2.9	32
1000	Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions. Journal of Alzheimer's Disease, 2019, 71, 715-732.	2.6	89
1001	AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention. Progress in Molecular Biology and Translational Science, 2019, 165, 63-106.	1.7	10
1002	InÂvivo measures of tau burden are associated with atrophy in early Braak stage medial temporal lobe regions in amyloid-negative individuals. Alzheimer's and Dementia, 2019, 15, 1286-1295.	0.8	24
1003	Altered microglia and neurovasculature in the Alzheimer's disease cerebellum. Neurobiology of Disease, 2019, 132, 104589.	4.4	36
1004	<p>Associations of informant-based sleep reports with Alzheimer's disease pathologies</p>. Clinical Interventions in Aging, 2019, Volume 14, 1631-1642.	2.9	8

#	ARTICLE	IF	CITATIONS
1005	Regional brain atrophy predicts time to conversion to Alzheimer's disease, dependent on baseline volume. <i>Neurobiology of Aging</i> , 2019, 83, 86-94.	3.1	20
1006	Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1132-1138.	6.4	16
1007	Contributions by the Brain Renin-Angiotensin System to Memory, Cognition, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 469-480.	2.6	54
1008	The trinity of tau, trauma, and time. <i>Lancet Neurology</i> , The, 2019, 18, 715-717.	10.2	0
1009	Sleep as a Potential Biomarker of Tau and β^2 -Amyloid Burden in the Human Brain. <i>Journal of Neuroscience</i> , 2019, 39, 6315-6324.	3.6	160
1010	Development of a mnemonic discrimination task using naturalistic stimuli with applications to aging and preclinical Alzheimer's disease. <i>Learning and Memory</i> , 2019, 26, 219-228.	1.3	17
1011	The value of hippocampal volume, shape, and texture for 11-year prediction of dementia: a population-based study. <i>Neurobiology of Aging</i> , 2019, 81, 58-66.	3.1	8
1012	Improving Sensitivity and Specificity of Amyloid- β^2 Peptides and Tau Protein Detection with Antibiofouling Magnetic Nanoparticles for Liquid Biopsy of Alzheimer's Disease. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 3595-3605.	5.2	22
1013	Neuroimaging Biomarkers for Alzheimer's Disease. <i>Molecular Neurodegeneration</i> , 2019, 14, 21.	10.8	161
1014	Subthreshold amyloid and its biological and clinical meaning. <i>Neurology</i> , 2019, 93, 72-79.	1.1	39
1015	Navigating the future of clinical assessments. <i>Brain</i> , 2019, 142, 1491-1502.	7.6	4
1016	Subcortical amyloid load is associated with shape and volume in cognitively normal individuals. <i>Human Brain Mapping</i> , 2019, 40, 3951-3965.	3.6	9
1017	Alzheimer's pathology targets distinct memory networks in the ageing brain. <i>Brain</i> , 2019, 142, 2492-2509.	7.6	131
1018	Cerebrospinal fluid from Alzheimer's disease patients promotes tau aggregation in transgenic mice. <i>Acta Neuropathologica Communications</i> , 2019, 7, 72.	5.2	16
1019	The interplay of biochemical and biomechanical degeneration in Alzheimer's disease. <i>Computer Methods in Applied Mechanics and Engineering</i> , 2019, 352, 369-388.	6.6	23
1020	Emotion regulation via visual avoidance: Insights from neurological patients. <i>Neuropsychologia</i> , 2019, 131, 91-101.	1.6	7
1021	Reverting Metabolic Dysfunction in Cortex and Cerebellum of APP/PS1 Mice, a Model for Alzheimer's Disease by Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma (PPAR γ) Agonist. <i>Molecular Neurobiology</i> , 2019, 56, 7267-7283.	4.0	25
1022	Photo-oxygenation inhibits tau amyloid formation. <i>Chemical Communications</i> , 2019, 55, 6165-6168.	4.1	26

#	ARTICLE	IF	CITATIONS
1023	Differential Effects of BMI on Brain Response to Odor in Olfactory, Reward and Memory Regions: Evidence from fMRI. <i>Nutrients</i> , 2019, 11, 926.	4.1	24
1024	Impaired Autophagic Degradation of Transforming Growth Factor- β 2-Induced Protein by Macrophages in Lattice Corneal Dystrophy. , 2019, 60, 978.		4
1025	Mind the gaps: What we don't know about cognitive impairment in essential tremor. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 10-19.	2.2	47
1026	The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?. <i>Acta Neuropathologica Communications</i> , 2019, 7, 31.	5.2	49
1027	Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy. <i>EBioMedicine</i> , 2019, 42, 157-173.	6.1	38
1028	Effect of Off-Target Binding on 18 F-Flortaucipir Variability in Healthy Controls Across the Life Span. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1444-1451.	5.0	96
1029	Fungal Metabolites as Promising New Drug Leads for the Treatment of Alzheimer's Disease. <i>Studies in Natural Products Chemistry</i> , 2019, , 1-39.	1.8	4
1030	Measures of Diffusion Tensor Tractography of Regions Associated with Default Mode Network in Alzheimer's Disease. , 2019, , 29-40.		0
1031	Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 339-348.	2.8	16
1032	Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study. <i>BMC Geriatrics</i> , 2019, 19, 380.	2.7	21
1033	Tau pathology in the medial temporal lobe of athletes with chronic traumatic encephalopathy: a chronic effects of neurotrauma consortium study. <i>Acta Neuropathologica Communications</i> , 2019, 7, 207.	5.2	15
1034	Functional Connectivity between the Resting-State Olfactory Network and the Hippocampus in Alzheimer's Disease. <i>Brain Sciences</i> , 2019, 9, 338.	2.3	37
1035	Zinc Binding to Tau Influences Aggregation Kinetics and Oligomer Distribution. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5979.	4.1	25
1036	Increased Inflammation and Unchanged Density of Synaptic Vesicle Glycoprotein 2A (SV2A) in the Postmortem Frontal Cortex of Alzheimer's Disease Patients. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 538.	3.7	25
1037	Hippocampus Radiomic Biomarkers for the Diagnosis of Amnesic Mild Cognitive Impairment: A Machine Learning Method. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 323.	3.4	24
1038	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 3-17.	2.2	82
1039	Brain MR Radiomics to Differentiate Cognitive Disorders. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 210-219.	1.8	22
1040	Tau PET imaging in neurodegenerative tauopathiesâ€”still a challenge. <i>Molecular Psychiatry</i> , 2019, 24, 1112-1134.	7.9	409

#	ARTICLE	IF	CITATIONS
1041	Sensorineural Impairments, Cardiovascular Risk Factors, and 10-Year Incidence of Cognitive Impairment and Decline in Midlife: The Beaver Dam Offspring Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1786-1792.	3.6	28
1042	ABCA7 risk variant in healthy older African Americans is associated with a functionally isolated entorhinal cortex mediating deficient generalization of prior discrimination training. <i>Hippocampus</i> , 2019, 29, 527-538.	1.9	21
1043	The clinical relevance of visualising the peripheral retina. <i>Progress in Retinal and Eye Research</i> , 2019, 68, 83-109.	15.5	91
1044	Olfactory and other sensory impairments in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2019, 15, 11-24.	10.1	234
1045	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 181-195.	2.6	48
1046	Relationships Between Tau and Glucose Metabolism Reflect Alzheimer's Disease Pathology in Cognitively Normal Older Adults. <i>Cerebral Cortex</i> , 2019, 29, 1997-2009.	2.9	61
1047	Coffee polyphenols prevent cognitive dysfunction and suppress amyloid β^2 plaques in APP/PS2 transgenic mouse. <i>Neuroscience Research</i> , 2020, 154, 35-44.	1.9	47
1048	A comprehensive study of mobile-health based assistive technology for the healthcare of dementia and Alzheimer's disease (AD). <i>Health Care Management Science</i> , 2020, 23, 287-309.	2.6	75
1049	Psychiatric Manifestations With Sacubitril/Valsartan: A Case Report. <i>Journal of Pharmacy Practice</i> , 2020, 33, 553-557.	1.0	4
1050	A third of community-dwelling elderly with intermediate and high level of Alzheimer's neuropathologic changes are not demented: A meta-analysis. <i>Ageing Research Reviews</i> , 2020, 58, 101002.	10.9	15
1051	Reelin in the Years: decline in the number of reelin immunoreactive neurons in layer II of the entorhinal cortex in aged monkeys with memory impairment. <i>Neurobiology of Aging</i> , 2020, 87, 132-137.	3.1	24
1052	To stage, or not to stage. <i>Current Opinion in Neurobiology</i> , 2020, 61, 10-22.	4.2	37
1053	Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 3.	6.2	22
1054	Human subiculo-fornico-mamillary system in Alzheimer's disease: Tau seeding by the pillar of the fornix. <i>Acta Neuropathologica</i> , 2020, 139, 443-461.	7.7	10
1055	Amyloid- β^2 -independent regulators of tau pathology in Alzheimer disease. <i>Nature Reviews Neuroscience</i> , 2020, 21, 21-35.	10.2	338
1056	Aging and Alzheimer's disease pathology. <i>Neuropathology</i> , 2020, 40, 22-29.	1.2	166
1057	Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 272.	3.4	17
1058	18F-MK-6240 PET for early and late detection of neurofibrillary tangles. <i>Brain</i> , 2020, 143, 2818-2830.	7.6	147

#	ARTICLE	IF	CITATIONS
1059	Effect of A/T/N imaging biomarkers on impaired odor identification in Alzheimer's disease. Scientific Reports, 2020, 10, 11556.	3.3	9
1060	Comparison of 1.5T and 3T MRI hippocampus texture features in the assessment of Alzheimer's disease. Biomedical Signal Processing and Control, 2020, 62, 102098.	5.7	6
1061	Synergy between amyloid- β^2 and tau in Alzheimer's disease. Nature Neuroscience, 2020, 23, 1183-1193.	14.8	579
1062	Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers. Journal of Nuclear Medicine, 2020, 61, 1413-1418.	5.0	17
1063	Diffusion tensor-MRI detects exercise-induced neuroplasticity in the hippocampal microstructure in mice. Brain Plasticity, 2020, 5, 147-159.	3.5	10
1064	Does amnesia specifically predict Alzheimer's pathology? A neuropathological study. Neurobiology of Aging, 2020, 95, 123-130.	3.1	15
1065	18F-Florbetaben Amyloid PET Imaging: A Chinese Study in Cognitive Normal Controls, Mild Cognitive Impairment, and Alzheimer's Disease Patients. Frontiers in Neuroscience, 2020, 14, 745.	2.8	6
1066	Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline. Annals of Neurology, 2020, 88, 921-932.	5.3	63
1067	Axonal Degeneration in AD: The Contribution of A β^2 and Tau. Frontiers in Aging Neuroscience, 2020, 12, 581767.	3.4	28
1068	Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus. Movement Disorders, 2020, 35, 1945-1954.	3.9	27
1069	Wnt Signaling Pathway Dysregulation in the Aging Brain: Lessons From the Octodon degus. Frontiers in Cell and Developmental Biology, 2020, 8, 734.	3.7	23
1070	Mechanisms of Pathogenic Tau and A β^2 Protein Spreading in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 265.	3.4	78
1071	Contribution of iron and A β^2 to age differences in entorhinal and hippocampal subfield volume. Neurology, 2020, 95, e2586-e2594.	1.1	11
1072	The Peripheral Hearing and Central Auditory Processing Skills of Individuals With Subjective Memory Complaints. Frontiers in Neuroscience, 2020, 14, 888.	2.8	7
1073	Dementia-related psychosis and the potential role for pimavanserin. CNS Spectrums, 2022, 27, 7-15.	1.2	8
1074	The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29133-29143.	7.1	24
1075	Change in Expression of 5-HT ₆ Receptor at Different Stages of Alzheimer's Disease: A Postmortem Study with the PET Radiopharmaceutical [18F]2FNQ1P. Journal of Alzheimer's Disease, 2020, 75, 1329-1338.	2.6	1
1076	Clinical significance of fluid biomarkers in Alzheimer's Disease. Pharmacological Reports, 2020, 72, 528-542.	3.3	22

#	ARTICLE	IF	CITATIONS
1077	Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 55.	6.2	21
1078	Older, non-demented apolipoprotein E4 carrier males show hyperactivation and structural differences in odor memory regions: a blood-oxygen-level-dependent and structural magnetic resonance imaging study. <i>Neurobiology of Aging</i> , 2020, 93, 25-34.	3.1	4
1079	Targeting tau: Clinical trials and novel therapeutic approaches. <i>Neuroscience Letters</i> , 2020, 731, 134919.	2.1	63
1080	Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults. <i>NeuroImage</i> , 2020, 220, 116991.	4.2	31
1081	Interest of biological biomarkers in the diagnostic approach of neurocognitive disorders in the elderly. <i>Revue Neurologique</i> , 2020, 176, 677-683.	1.5	9
1082	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. <i>British Journal of Anaesthesia</i> , 2020, 124, 594-602.	3.4	14
1083	Prediction of rapid amyloid and phosphorylated tau accumulation in cognitively healthy individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12019.	2.4	10
1084	Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease. <i>Brain</i> , 2020, 143, 1233-1248.	7.6	164
1085	Assessment of Alzheimer's Disease Based on Texture Analysis of the Entorhinal Cortex. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 176.	3.4	23
1086	Up-regulation of neprilysin mediates the protection of fructo-oligosaccharides against Alzheimer's disease. <i>Food and Function</i> , 2020, 11, 6565-6572.	4.6	7
1087	Race modifies default mode connectivity in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2020, 9, 8.	8.0	16
1088	Permutation Entropy and Statistical Complexity in Mild Cognitive Impairment and Alzheimer's Disease: An Analysis Based on Frequency Bands. <i>Entropy</i> , 2020, 22, 116.	2.2	16
1089	5-Caffeoylquinic Acid Ameliorates Cognitive Decline and Reduces A β Deposition by Modulating A β Clearance Pathways in APP/PS2 Transgenic Mice. <i>Nutrients</i> , 2020, 12, 494.	4.1	34
1090	Automatic classification of cognitively normal, mild cognitive impairment and Alzheimer's disease using structural MRI analysis. <i>Informatics in Medicine Unlocked</i> , 2020, 18, 100305.	3.4	55
1091	Correlation between regional brain volume and olfactory function in very mild amnesic patients. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116686.	0.6	6
1092	Respiratory Disease and Lower Pulmonary Function as Risk Factors for Dementia. <i>Chest</i> , 2020, 157, 1538-1558.	0.8	45
1093	Imaging Tau Pathology—The Next Step. <i>JAMA Neurology</i> , 2020, 77, 796.	9.0	6
1094	Synthesis, biological evaluation and preclinical study of a novel ^{99m} Tc-peptide: A targeting probe of amyloid- β plaques as a possible diagnostic agent for Alzheimer's disease. <i>Bioorganic Chemistry</i> , 2020, 99, 103857.	4.1	10

#	ARTICLE	IF	CITATIONS
1095	Neuronal volume of the hippocampal regions in ageing. <i>Journal of Anatomy</i> , 2020, 237, 301-310.	1.5	6
1096	Automatic assessment of Alzheimer's disease diagnosis based on deep learning techniques. <i>Computers in Biology and Medicine</i> , 2020, 120, 103764.	7.0	71
1097	In vivo network models identify sex differences in the spread of tau pathology across the brain. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12016.	2.4	14
1098	Neuroimaging Detectable Differences between Parkinson's Disease Motor Subtypes: A Systematic Review. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 175-192.	1.5	25
1099	Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance. <i>European Journal of Medicinal Chemistry</i> , 2021, 209, 112915.	5.5	48
1100	Clinicopathological Staging of Dynamics of Neurodegeneration and Neuronal Loss in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 21-44.	1.7	8
1101	Increased dynamic flexibility in the medial temporal lobe network following an exercise intervention mediates generalization of prior learning. <i>Neurobiology of Learning and Memory</i> , 2021, 177, 107340.	1.9	10
1102	Design and overview of the Origins of Alzheimer's Disease Across the Life course (ORACLE) study. <i>European Journal of Epidemiology</i> , 2021, 36, 117-127.	5.7	6
1103	Association of Early β -Amyloid Accumulation and Neuroinflammation Measured With [¹¹ C]PBR28 in Elderly Individuals Without Dementia. <i>Neurology</i> , 2021, 96, e1608-e1619.	1.1	30
1104	Higher midlife CAIDE score is associated with increased brain atrophy in a cohort of cognitively healthy middle-aged individuals. <i>Journal of Neurology</i> , 2021, 268, 1962-1971.	3.6	7
1105	Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome. <i>NeuroImage: Clinical</i> , 2021, 31, 102740.	2.7	9
1106	Tauvid,®: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease. <i>Pharmaceuticals</i> , 2021, 14, 110.	3.8	56
1107	Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. , 2021, , 367-412.		0
1108	Memory Resilience in Alzheimer Disease With Primary Progressive Aphasia. <i>Neurology</i> , 2021, 96, e916-e925.	1.1	14
1109	Leptin regulation of hippocampal synaptic function in health and disease. <i>Vitamins and Hormones</i> , 2021, 115, 105-127.	1.7	7
1110	Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2097-2109.	6.4	34
1111	Olfactory impairment in men and mice related to aging and amyloid-induced pathology. <i>Pflugers Archiv European Journal of Physiology</i> , 2021, 473, 805-821.	2.8	12
1112	The Role of Microglia in Sporadic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 961-968.	2.6	43

#	ARTICLE	IF	CITATIONS
1113	Reduced Repetition Suppression in Aging is Driven by Tau-Related Hyperactivity in Medial Temporal Lobe. <i>Journal of Neuroscience</i> , 2021, 41, 3917-3931.	3.6	16
1114	Correlation between cerebral blood flow and olfactory function in mild cognitive impairment and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1103-1109.	2.7	7
1116	Molecular Imaging Approaches in Dementia. <i>Radiology</i> , 2021, 298, 517-530.	7.3	27
1117	Particulate Matter Exposure Exacerbates Amyloid- β Plaque Deposition and Gliosis in APP/PS1 Mice. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 761-774.	2.6	33
1118	Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI) Tj ETQq0 0.0 rgBT /Overlock 10	6.0	77
1119	Early detection of amyloid load using 18F-florbetaben PET. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 67.	6.2	26
1120	Alzheimer's Disease Pathogenesis: Role of Autophagy and Mitophagy Focusing in Microglia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3330.	4.1	71
1121	Gray matter structural networks related to 18F-THK5351 retention in cognitively normal older adults and Alzheimer's disease patients. <i>ENeurologicalSci</i> , 2021, 22, 100309.	1.3	4
1122	Cerebellar Calcium-Binding Protein and Neurotrophin Receptor Defects in Down Syndrome and Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 645334.	3.4	10
1123	The Causal Role of Lipoxidative Damage in Mitochondrial Bioenergetic Dysfunction Linked to Alzheimer's Disease Pathology. <i>Life</i> , 2021, 11, 388.	2.4	16
1124	EEG alterations during wake and sleep in mild cognitive impairment and Alzheimer's disease. <i>IScience</i> , 2021, 24, 102386.	4.1	34
1125	What do we know about the risks of developing dementia after traumatic brain injury?. <i>Minerva Medica</i> , 2021, 112, 288-297.	0.9	2
1126	Bridging Scales in Alzheimer's Disease: Biological Framework for Brain Simulation With The Virtual Brain. <i>Frontiers in Neuroinformatics</i> , 2021, 15, 630172.	2.5	20
1127	Increasing the confidence of 18F-Florbetaben PET interpretations: Machine learning quantitative approximation. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2022, 41, 153-163.	0.2	1
1128	Correlation of [18F]florbetaben textural features and age of onset of Alzheimer's disease: a principal components analysis approach. <i>EJNMMI Research</i> , 2021, 11, 40.	2.5	3
1129	Structural and Functional Disruption of Salience Network in Distinguishing Subjective Cognitive Decline and Amnesic Mild Cognitive Impairment. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1384-1394.	3.5	15
1130	Hearing Impairment and Cognition in an Aging World. <i>JARO - Journal of the Association for Research in Otolaryngology</i> , 2021, 22, 387-403.	1.8	26
1131	Olfaction and Aging: A Review of the Current State of Research and Future Directions. <i>I-Perception</i> , 2021, 12, 204166952110203.	1.4	22

#	ARTICLE	IF	CITATIONS
1132	Advances in Brain Amyloid Imaging. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 241-252.	4.6	30
1133	PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 624330.	3.4	39
1134	Amyloid- β : a potential link between epilepsy and cognitive decline. <i>Nature Reviews Neurology</i> , 2021, 17, 469-485.	10.1	60
1135	Thiophene-Based Optical Ligands That Selectively Detect A β Pathology in Alzheimer's Disease. <i>ChemBioChem</i> , 2021, 22, 2568-2581.	2.6	8
1136	Dysregulated protein phosphorylation: A determining condition in the continuum of brain aging and Alzheimer's disease. <i>Brain Pathology</i> , 2021, 31, e12996.	4.1	33
1137	Hypothesis and Theory: Characterizing Abnormalities of Energy Metabolism Using a Cellular Platform as a Personalized Medicine Approach for Alzheimer's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 697578.	3.7	4
1138	The potential role of glial cells in driving the prion-like transcellular propagation of tau in tauopathies. <i>Brain, Behavior, & Immunity - Health</i> , 2021, 14, 100242.	2.5	14
1140	Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe. <i>Brain</i> , 2021, 144, 2784-2797.	7.6	38
1141	Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer's disease alleviates amyloid-related pathologies in mice. <i>Nature Biomedical Engineering</i> , 2022, 6, 168-180.	22.5	27
1142	Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 541-560.	2.6	18
1143	Improved Causal Models of Alzheimer's Disease. , 2021, , .		2
1144	EP2 Antagonists (2011-2021): A Decade's Journey from Discovery to Therapeutics. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11816-11836.	6.4	21
1145	AND-Logic Strategy for Accurate Analysis of Alzheimer's Disease via Fluorescent Probe Lighted Up by Two Specific Biomarkers. <i>Analytical Chemistry</i> , 2021, 93, 11337-11345.	6.5	32
1146	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599.	30.7	235
1147	Convergent and Discriminant Validity of Default Mode Network and Limbic Network Perfusion in Amnesic Mild Cognitive Impairment Patients. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1797-1808.	2.6	4
1148	Deficits in short-term memory binding are detectable in individuals with brain amyloid deposition in the absence of overt neurodegeneration in the Alzheimer's disease continuum. <i>Brain and Cognition</i> , 2021, 152, 105749.	1.8	9
1149	Disease Modelling of Cognitive Outcomes and Biomarkers in the European Prevention of Alzheimer's Dementia Longitudinal Cohort. <i>Frontiers in Big Data</i> , 2021, 4, 676168.	2.9	5
1150	Beam orientation optimization for coherent X-ray scattering from distributed deep targets. <i>BioMedical Engineering OnLine</i> , 2021, 20, 92.	2.7	0

#	ARTICLE	IF	CITATIONS
1151	Apolipoprotein E ε4-related effects on cognition are limited to the Alzheimer's disease spectrum. <i>GeroScience</i> , 2022, 44, 195-209.	4.6	1
1152	Improved automated synthesis of [18F]FINH-Me via direct radio-fluorination and quality control for Aβ2-amyloid imaging. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 276-281.	0.7	1
1153	Olfactory dysfunction in Alzheimer's disease. <i>Medical Alphabet</i> , 2021, , 7-11.	0.2	0
1154	Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. <i>Brain</i> , 2021, 144, 3517-3528.	7.6	47
1155	The squirrel monkey model in clinical neuroscience. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 152-164.	6.1	9
1156	Content-specific vulnerability of recent episodic memories in Alzheimer's disease. <i>Neuropsychologia</i> , 2021, 160, 107976.	1.6	10
1157	Age affects white matter microstructure and episodic memory across the older adult lifespan. <i>Neurobiology of Aging</i> , 2021, 106, 282-291.	3.1	11
1158	Proteomic correlates of cortical thickness in cognitively normal individuals with normal and abnormal cerebrospinal fluid beta-amyloid1-42. <i>Neurobiology of Aging</i> , 2021, 107, 42-52.	3.1	2
1159	Cross-sectional associations of tau protein biomarkers with semantic and episodic memory in older adults without dementia: A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2021, 71, 101449.	10.9	6
1160	Sex differences in Alzheimer's disease: do differences in tau explain the verbal memory gap?. <i>Neurobiology of Aging</i> , 2021, 107, 70-77.	3.1	17
1161	Episodic memory and cortical amyloid pathology: PET study in cognitively discordant twin pairs. <i>Neurobiology of Aging</i> , 2021, 108, 122-132.	3.1	1
1162	Contributions of the neurological examination to the diagnosis of dementia in Down syndrome. , 2022, , 251-272.		0
1163	The aging brain and brain banking. , 2021, , 103-112.		0
1165	Relationship between amyloid and tau levels and its impact on tau spreading. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2225-2232.	6.4	30
1166	Detection of retinal and blood Aβ2 oligomers with nanobodies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12193.	2.4	16
1167	New Neuropathological Criteria for Alzheimer Disease. <i>Archives of Neurology</i> , 1998, 55, 1174-1176.	4.5	78
1169	Mechanisms of Microglial Activation by Amyloid Precursor Protein and its Proteolytic Fragments. , 2008, , 13-32.		11
1170	Metabolic Magnetic Resonance Imaging: A Case for Bioscales in Medicine. , 2011, , 911-928.		3

#	ARTICLE	IF	CITATIONS
1172	Movement Disorders in Alzheimer's Disease. , 2014, , 129-140.		1
1173	Argyrophilic Grain Disease. Advances in Experimental Medicine and Biology, 2001, , 39-58.	1.6	19
1174	Tau Pathology in Neurons and Glial Cells of Aged Baboons. Advances in Experimental Medicine and Biology, 2001, 487, 59-69.	1.6	10
1175	Temporal Sequence of Alzheimer's Disease-Related Pathology. Cerebral Cortex, 1999, , 475-512.	0.6	71
1176	Neuropathological Findings Associated with Long-Term HAART. , 2009, , 29-47.		4
1178	Amyloid Oligomers, Protofibrils and Fibrils. Sub-Cellular Biochemistry, 2019, 93, 471-503.	2.4	13
1179	PET Neuroimaging in Dementia Conditions. , 2021, , 211-282.		7
1180	PET Imaging of Translocator Protein Expression in Neurological Disorders. , 2021, , 1021-1040.		2
1183	The Pattern of Lesions During the Transition to the Symptomatic Phase and in Fully Developed Alzheimer's Disease. Advances in Anatomy, Embryology and Cell Biology, 2015, , 95-130.	1.6	2
1184	The Role of Aging in Alzheimer's Disease. , 2016, , 197-227.		12
1185	Towards the Early Diagnosis of Alzheimer's Disease via a Multicriteria Classification Model. Lecture Notes in Computer Science, 2009, , 393-406.	1.3	17
1186	The Limbic System. , 2011, , 633-710.		2
1187	Demenz. , 2017, , 1377-1465.		1
1188	Evolution of neuronal changes in the course of Alzheimer's disease. Journal of Neural Transmission Supplementum, 1998, 53, 127-140.	0.5	404
1189	Prevention of Alzheimer's Disease and Alzheimer's Dementia. Mental Health and Illness Worldwide, 2016, , 1-26.	0.1	1
1190	Patterns of Cortical Neurodegeneration in Alzheimer's Disease: Subgroups, Subtypes, and Implications for Staging Strategies. , 2001, , 111-129.		5
1191	Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. NeuroImage, 2017, 157, 448-463.	4.2	341
1193	Reduced mind-wandering in mild cognitive impairment: Testing the spontaneous retrieval deficit hypothesis.. Neuropsychology, 2018, 32, 711-723.	1.3	17

#	ARTICLE	IF	CITATIONS
1194	Narrative video scene description task discriminates between levels of cognitive impairment in Alzheimer's disease.. Neuropsychology, 2020, 34, 437-446.	1.3	8
1195	14 Amyloid Imaging and (What is "Normal"?) Aging. , 2009, , 191-244.		2
1196	DS-GCNs: Connectome Classification using Dynamic Spectral Graph Convolution Networks with Assistant Task Training. Cerebral Cortex, 2021, 31, 1259-1269.	2.9	19
1197	Magnetic Resonance Imaging Relaxation Times and Gadolinium-DTPA Relaxivity Values in Human Cerebrospinal Fluid. Investigative Radiology, 1998, 33, 153-162.	6.2	13
1198	Distinct Patterns and Clinical Implications of Semantic Memory Deterioration Among Patients With MCI. Alzheimer Disease and Associated Disorders, 2015, 29, 124-134.	1.3	6
1201	Distinguishing cognitive impairment by using singularity spectrum and lacunarity analysis of the retinal vascular network. Neurophotonics, 2019, 6, 1.	3.3	5
1202	Neurodegeneration in Normal Brain Aging and Disease. Science of Aging Knowledge Environment: SAGE KE, 2004, 2004, pe26-pe26.	0.8	106
1203	Thinking laterally about neurodegenerative proteinopathies. Journal of Clinical Investigation, 2013, 123, 1847-1855.	8.2	98
1204	Voxel-based correlation of 18F-THK5351 accumulation and gray matter volume in the brain of cognitively normal older adults. EJNMMI Research, 2019, 9, 81.	2.5	4
1205	Normal Pressure Hydrocephalus. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 165-186.	0.8	24
1206	Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, <i>APOE</i> ϵ 4, and Cognitive Impairment. Neurology, 2021, 96, e975-e985.	1.1	42
1207	An MRI-Derived Definition of MCI-to-AD Conversion for Long-Term, Automatic Prognosis of MCI Patients. PLoS ONE, 2011, 6, e25074.	2.5	38
1208	Intravenous Delivery of Targeted Liposomes to Amyloid- β Pathology in APP/PSEN1 Transgenic Mice. PLoS ONE, 2012, 7, e48515.	2.5	56
1209	Long-Term Oral Administration of Hop Flower Extracts Mitigates Alzheimer Phenotypes in Mice. PLoS ONE, 2014, 9, e87185.	2.5	21
1210	Chronic Traumatic Encephalopathy in Contact Sports: A Systematic Review of All Reported Pathological Cases. PLoS ONE, 2015, 10, e0117338.	2.5	129
1211	Longitudinal Magnetic Resonance Imaging Studies of Older Adults: A Shrinking Brain. Journal of Neuroscience, 2003, 23, 3295-3301.	3.6	1,168
1212	A β Plaques. Free Neuropathology, 2020, 1, .	3.0	21
1213	Smell and taste recognition in early stages of late-onset Alzheimer's disease. SURG Journal, 2010, 4, 57-64.	0.1	1

#	ARTICLE	IF	CITATIONS
1214	Prion-like Mechanisms in Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 755-764.	1.4	27
1215	Impaired Functional Connectivity of the Thalamus in Alzheimer's Disease and Mild Cognitive Impairment: A Resting-State fMRI Study. Current Alzheimer Research, 2013, 10, 754-766.	1.4	106
1216	Myelin Injury and Degraded Myelin Vesicles in Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 232-238.	1.4	60
1217	Insulin Resistance in Brain and Possible Therapeutic Approaches. Current Vascular Pharmacology, 2014, 12, 553-564.	1.7	36
1219	Mild cognitive impairment: historical development and summary of research. Dialogues in Clinical Neuroscience, 2004, 6, 351-367.	3.7	42
1220	Is there a neuropathology difference between mild cognitive impairment and dementia?. Dialogues in Clinical Neuroscience, 2009, 11, 171-179.	3.7	38
1221	Neurobiological consequences of traumatic brain injury. Dialogues in Clinical Neuroscience, 2011, 13, 287-300.	3.7	329
1222	Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behavioural Neurology, 2009, 21, 117-28.	2.1	125
1223	Psychiatric Disorders and Traumatic Brain Injury: What Is the Connection?. Psychiatric Annals, 2010, 40, 533-539.	0.1	2
1224	Body fluid biomarkers in Alzheimer's disease. Annals of Translational Medicine, 2015, 3, 70.	1.7	17
1225	Prevalence of hippocampal morphologic variants between healthy elderly subjects and patients with Alzheimer's disease. Advanced Biomedical Research, 2014, 3, 59.	0.5	3
1226	Toll-Like Receptor Signaling in Alzheimer's Disease Progression. , 2012, 01, .		2
1227	Alzheimer's disease: an evolutionary approach. Journal of Anthropological Sciences, 2013, 91, 135-57.	0.4	24
1228	Cortical tau deposition follows patterns of entorhinal functional connectivity in aging. ELife, 2019, 8, .	6.0	83
1229	Cross-Sectional and Longitudinal Comparisons of Biomarkers and Cognition Among Asymptomatic Middle-Aged Individuals with a Parental History of Either Autosomal Dominant or Late Onset Alzheimer Disease. SSRN Electronic Journal, 0, , .	0.4	0
1230	Brain-printing biometrics underlying mechanism as an early diagnostic technique for Alzheimer's disease neurodegenerative type. Current Research in Physiology, 2021, 4, 216-222.	1.7	6
1231	Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults. Alzheimer's Research and Therapy, 2021, 13, 174.	6.2	15
1232	Olfactory Measures as Predictors of Conversion to Mild Cognitive Impairment and Alzheimer's Disease. Brain Sciences, 2021, 11, 1391.	2.3	10

#	ARTICLE	IF	CITATIONS
1233	Strategies to delay the onset of Alzheimer's disease. <i>Exs</i> , 2000, 89, 211-225.	1.4	1
1235	Title is missing!. <i>Okayama Igakkai Zasshi</i> , 2006, 118, 193-198.	0.0	0
1236	Les lésions de la maladie d'Alzheimer. Perspectives thérapeutiques ?. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2008, 192, 303-321.	0.0	3
1237	Microstructural Imaging of Neurodegenerative Changes. , 2009, , 95-117.		1
1238	「1/4Žè,,3çŸçµŒç-3/4æ,Łā«āāā,āfā,ā,āfžāf1/4ā,«āf1/4. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2010, 41, 101-		
1240	The Genetics of Alzheimer's Disease and Parkinson's Disease. <i>Advances in Neurobiology</i> , 2011, , 695-755. 1.8		7
1242	Demenz. , 2011, , 1240-1319.		0
1244	Morbus Alzheimer und Altersveränderungen des Gehirns. , 2012, , 193-208.		0
1245	Cognitive and Behavioural Predictors of Alzheimer's Disease Progression. <i>European Neurological Review</i> , 2012, 7, 103.	0.5	0
1246	Towards the Early Diagnosis of Alzheimer's Disease through the Application of a Multicriteria Classification Model. , 0, , .		1
1247	Alzheimer's Disease: Approaches to Pathogenesis in the Genomic Age. , 0, , .		0
1248	Analysis of affective disorders in patients with vascular dementia. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2014, .	1.2	1
1249	PET Imaging of Translocator Protein Expression in Neurological Disorders. , 2014, , 653-667.		0
1250	Cerebral ageing-the role of insulin and insulin-like growth factor signalling: A review. <i>World Journal of Neurology</i> , 2014, 4, 12.	0.6	0
1251	Die Verbindung von PTSD und aktueller gerontopsychiatrischer Symptomatik an Fallbeispielen. , 2014, , 251-262.		1
1252	Aβ Imaging in Aging, Alzheimer's Disease and Other Neurodegenerative Conditions. , 2014, , 213-254.		2
1253	Cognitive Decline Associated with Aging, Alzheimer's Disease and Cerebrovascular Risk: Advantages of Dynamic Imaging with MEG. , 2014, , 657-676.		1
1254	PET Imaging in Neuroinflammation. , 2014, , 205-216.		0

#	ARTICLE	IF	CITATIONS
1255	Effects of nicotinic cholinergic system manipulations on paired-associate learning (PAL) in mice. SURG Journal, 2014, 7, 33-46.	0.1	0
1256	Modern approach in the therapy of Alzheimer's disease. UĖenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2014, 21, 6-10.	0.2	0
1258	AlzheimerĖ™s Disease Dementia, Amyloid Imaging and Underpinning Fibrillar AĖ² Plaque Associated Pathology: Are They Aligned?. Journal of Neurology & Stroke, 0, , .	0.1	0
1259	Prions et transconformation protĖ©ique: une perspective historique. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 787-796.	0.0	0
1260	Unproven Hypotheses on the Cause of AlzheimerĖ™s. , 2016, , 39-48.		0
1261	Ė„lter werden mit psychotischen Erkrankungen. , 2016, , 299-311.		1
1262	Demenz. , 2016, , 1-89.		0
1264	Prevention of AlzheimerĖ™s Disease and AlzheimerĖ™s Dementia. Mental Health and Illness Worldwide, 2017, , 549-574.	0.1	0
1267	Tau Imaging in Preclinical AlzheimerĖ™s Disease. Neuromethods, 2018, , 189-197.	0.3	0
1269	Cognitive Decline Associated with Aging, AlzheimerĖ™s Disease, and Cerebrovascular Risk: Advantages of Dynamic Imaging with MEG. , 2019, , 1099-1119.		0
1270	Cognitive Decline Associated with Aging, AlzheimerĖ™s Disease, and Cerebrovascular Risk: Advantages of Dynamic Imaging with MEG. , 2019, , 1-20.		1
1274	The meaning of blood and cerebrospinal fluid biomarkers in early diagnosis of Alzheimer's disease. Journal of Education, Health and Sport, 2020, 10, 308.	0.1	1
1275	Cerebrospinal fluid and blood biomarkers in the diagnostic assays of AlzheimerĖ™s disease. Journal of Innovative Optical Health Sciences, 2022, 15, .	1.0	9
1276	Role of Forkhead Transcription Factors of the O Class (FoxO) in Development and Progression of AlzheimerĖ™s Disease. CNS and Neurological Disorders - Drug Targets, 2020, 19, 709-721.	1.4	6
1277	Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 414-421.	0.7	5
1278	Bacopa monnieri: The Neuroprotective Elixir from the EastĖ”Phytochemistry, Pharmacology, and Biotechnological Improvement. , 2020, , 97-126.		2
1279	The Limbic System. , 2020, , 745-830.		3
1280	AĖ² Imaging in Aging, AlzheimerĖ™s Disease, and Other Neurodegenerative Conditions. , 2021, , 283-343.		0

#	ARTICLE	IF	CITATIONS
1281	Neuroimaging Findings in Mild Cognitive Impairment. , 2021, , 367-425.		1
1283	Neuropathology of non-Alzheimer degenerative disorders. International Journal of Clinical and Experimental Pathology, 2009, 3, 1-23.	0.5	68
1286	Mild cognitive impairment: The dilemma. Indian Journal of Psychiatry, 2009, 51 Suppl 1, S44-51.	0.7	8
1289	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Emergence of the Solution to an Important Unmet Need. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2013, 24, 97-104.	0.7	4
1290	Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future. Journal of Pharmaceutical and Biomedical Analysis, 2022, 209, 114479.	2.8	13
1291	Amyloid Imaging in Dementia and Neurodegenerative Disease. , 2022, , 99-110.		1
1292	Structural and functional brain alterations associated with cancer-associated cognitive decline in gastric cancer patients: A preliminary longitudinal neuroimaging study. Brain and Behavior, 2022, 12, e2437.	2.2	2
1293	Tau Imaging in Neurodegenerative Dementia. , 2022, , 111-120.		0
1294	Post-translational modifications within tau paired helical filament nucleating motifs perturb microtubule interactions and oligomer formation. Journal of Biological Chemistry, 2022, 298, 101442.	3.4	16
1295	Spatial Pattern Separation Testing Differentiates Alzheimer's Disease Biomarker-Positive and Biomarker-Negative Older Adults With Amnesic Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 774600.	3.4	5
1296	Aumento de la confianza en la interpretación del PET con 18F-Florbetaben: un machine learning basado en la aproximación cuantitativa. Revista Española De Medicina Nuclear E Imagen Molecular, 2022, 41, 153-163.	0.0	1
1297	The Effect of Olfactory Training on Olfaction, Cognition, and Brain Function in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2022, 85, 745-754.	2.6	6
1298	Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective. International Journal of Molecular Sciences, 2021, 22, 13002.	4.1	14
1299	Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention. Ageing Research Reviews, 2022, 74, 101544.	10.9	60
1300	Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer's Disease Biomarkers and Mood Symptoms. Frontiers in Aging Neuroscience, 2021, 13, 806432.	3.4	7
1301	Can the entorhinal cortex help distinguish healthy aging brains from pathological aging brains?. Aging Brain, 2022, 2, 100026.	1.3	0
1302	Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [18F]-S16 in Healthy Volunteers and Its Application in Assessment of Tau Pathology in Alzheimer's Disease. Frontiers in Bioengineering and Biotechnology, 2021, 9, 812818.	4.1	5
1305	Temporal dynamics of animacy categorization in the brain of patients with mild cognitive impairment. PLoS ONE, 2022, 17, e0264058.	2.5	3

#	ARTICLE	IF	CITATIONS
1307	Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease. <i>Neuropsychopharmacology</i> , 2022, 47, 1128-1136.	5.4	30
1308	Executive Functions in Alzheimer's Disease: A Systematic Review. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 81-99.	2.2	1
1309	Overview of tau PET molecular imaging. <i>Current Opinion in Neurology</i> , 2022, 35, 230-239.	3.6	18
1310	Delivery of Intravenously Administered Antibodies Targeting Alzheimer's Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis. <i>Pharmaceutics</i> , 2022, 14, 411.	4.5	12
1312	Disrupted connectivity in the olfactory bulb-entorhinal cortex-dorsal hippocampus circuit is associated with recognition memory deficit in Alzheimer's disease model. <i>Scientific Reports</i> , 2022, 12, 4394.	3.3	8
1315	Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer's Disease. <i>Biomolecules</i> , 2022, 12, 458.	4.0	9
1317	Low Subicular Volume as an Indicator of Dementia-Risk Susceptibility in Old Age. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 811146.	3.4	5
1318	Dementia classification using MR imaging and clinical data with voting based machine learning models. <i>Multimedia Tools and Applications</i> , 2022, 81, 25971-25992.	3.9	13
1319	Mesial temporal tau in amyloid- β -negative cognitively normal older persons. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 51.	6.2	12
1320	Bridging patterns of neurocognitive aging across the older adult lifespan. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 135, 104594.	6.1	6
1321	Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly. <i>Seminars in Cell and Developmental Biology</i> , 2022, 126, 125-137.	5.0	13
1322	Stress Response and Hearing Loss Differentially Contribute to Dynamic Alterations in Hippocampal Neurogenesis and Microglial Reactivity in Mice Exposed to Acute Noise Exposure. <i>Frontiers in Neuroscience</i> , 2021, 15, 749925.	2.8	5
1323	Structural and Functional Abnormalities of Olfactory-Related Regions in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 361-374.	2.1	20
1324	Distinct Factors Drive the Spatiotemporal Progression of Tau Pathology in Older Adults. <i>Journal of Neuroscience</i> , 2022, 42, 1352-1361.	3.6	7
1325	Amylin Pharmacology in Alzheimer's Disease Pathogenesis and Treatment. <i>Current Neuropharmacology</i> , 2021, 19, .	2.9	1
1336	Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). <i>Neurogenetics</i> , 2000, 2, 193-205.	1.4	83
1337	Recent Trends in Nano-Particulate Carriers for the Diagnosis and Treatment of Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 477-499.	1.4	1
1338	Hearing Loss and Cognition: What We Know and Where We Need to Go. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 769405.	3.4	47

#	ARTICLE	IF	CITATIONS
1339	Acquisition and consolidation of verbal learning and episodic memory as predictors of the conversion from mild cognitive impairment to probable Alzheimer's disease. <i>Aging, Neuropsychology, and Cognition</i> , 2023, 30, 638-653.	1.3	1
1340	Entorhinal Subfield Vulnerability to Neurofibrillary Tangles in Aging and the Preclinical Stage of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1379-1399.	2.6	9
1341	Selective inhibition of phosphodiesterase 4D increases tau phosphorylation at Ser214 residue. <i>BioFactors</i> , 2022, , .	5.4	3
1342	Association between lower body temperature and increased tau pathology in cognitively normal older adults. <i>Neurobiology of Disease</i> , 2022, 171, 105748.	4.4	3
1343	Brain simulation augments machine-learning-based classification of dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	3.7	10
1344	Recombinant Integrin β 1 Signal Peptide Blocks Gliosis Induced by A β Oligomers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5747.	4.1	1
1346	A History of Senile Plaques: From Alzheimer to Amyloid Imaging. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 387-413.	1.7	6
1349	Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. <i>Acta Neuropathologica</i> , 2022, 144, 27-44.	7.7	67
1350	Posterior cingulate cortex reveals an expression profile of resilience in cognitively intact elders. <i>Brain Communications</i> , 2022, 4, .	3.3	10
1351	Alterations of sleep oscillations in Alzheimer's disease: A potential role for GABAergic neurons in the cortex, hippocampus, and thalamus. <i>Brain Research Bulletin</i> , 2022, 187, 181-198.	3.0	13
1352	Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-11.	2.6	7
1355	Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78-94. <i>Molecular Psychiatry</i> , 2022, 27, 4335-4342.	7.9	4
1356	miR-143-3p Inhibits Aberrant Tau Phosphorylation and Amyloidogenic Processing of APP by Directly Targeting DAPK1 in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7992.	4.1	16
1357	Aging the brain: multi-region methylation principal component based clock in the context of Alzheimer's disease. <i>Aging</i> , 2022, 14, 5641-5668.	3.1	14
1358	Evaluation of tau deposition using 18F-Pi-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	9
1359	Adenosine receptor signalling in Alzheimer's disease. <i>Purinergic Signalling</i> , 2022, 18, 359-381.	2.2	5
1360	Cholesterol as a key player in amyloid β -mediated toxicity in Alzheimer's disease. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	2.9	21
1361	Brain ethanolamine phospholipids, neuropathology and cognition: A comparative post-mortem analysis of structurally specific plasmalogen and phosphatidyl species. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	1

#	ARTICLE	IF	CITATIONS
1362	Textural features reflecting local activity of the hippocampus improve the diagnosis of Alzheimer's disease and amnesic mild cognitive impairment: A radiomics study based on functional magnetic resonance imaging. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	6
1363	Microglia activation linking amyloid- β^2 drive tau spatial propagation in Alzheimer's disease. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	3
1364	Assessing mild cognitive impairment using object location memory in immersive virtual environments. <i>Hippocampus</i> , 2022, 32, 660-678.	1.9	6
1365	Clinical course and serum amyloid β^2 levels in elderly patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2022, 315, 156-161.	4.1	1
1366	Asymmetric amyloid deposition in preclinical Alzheimer's disease: A PET study. <i>Aging Brain</i> , 2022, 2, 100048.	1.3	2
1368	Somatic Mutations and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 475-493.	2.6	4
1369	Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	7
1371	Hypothesis review: Alzheimer's overture guidelines. <i>Brain Pathology</i> , 2023, 33, .	4.1	18
1372	Perivascular spaces as a potential biomarker of Alzheimer's disease. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	18
1373	Observational studies in Alzheimer disease: bridging preclinical studies and clinical trials. <i>Nature Reviews Neurology</i> , 0, , .	10.1	0
1374	Entorhinal-Hippocampal Circuit Integrity Is Related to Mnemonic Discrimination and Amyloid- β^2 Pathology in Older Adults. <i>Journal of Neuroscience</i> , 2022, 42, 8742-8753.	3.6	10
1375	Reduction of kinesin I heavy chain decreases tau hyperphosphorylation, aggregation, and memory impairment in Alzheimer's disease and tauopathy models. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	14
1376	Sex-Specific Protective Effects of Cognitive Reserve on Age-Related Cognitive Decline. <i>Neurology</i> , 2023, 100, .	1.1	1
1377	The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death. <i>Brain Research Bulletin</i> , 2022, 190, 204-217.	3.0	22
1379	PET molecular imaging for pathophysiological visualization in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 765-783.	6.4	18
1380	Review of Quantitative Methods for the Detection of Alzheimer's Disease with Positron Emission Tomography. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 11463.	2.5	1
1383	Topology of diffusion changes in corpus callosum in Alzheimer's disease: An exploratory case-control study. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	3
1384	Advanced Diagnostic Technique for Alzheimer's Disease using MRI Top-Ranked Volume and Surface-based Features. <i>Journal of Biomedical Physics and Engineering</i> , 2022, 12, .	0.9	0

#	ARTICLE	IF	CITATIONS
1385	Development of a simple screening tool for determining cognitive status in Alzheimer's disease. PLoS ONE, 2023, 18, e0280178.	2.5	1
1387	Potential Protective Function of A β ₄₂ Monomer on Tauopathies. Journal of the American Society for Mass Spectrometry, 2023, 34, 472-483.	2.8	1
1389	Cortical amyloid-beta burden is associated with changes in intracortical myelin in cognitively normal older adults. Translational Psychiatry, 2023, 13, .	4.8	1
1390	Early Detection of Alzheimer's Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers. Journal of Alzheimer's Disease, 2023, 92, 1077-1091.	2.6	3
1391	Cognitive reserve moderates the association between cerebral blood flow and language performance in older adults with mild cognitive impairment. Neurobiology of Aging, 2023, 125, 83-89.	3.1	2
1392	The unique neuropathological vulnerability of the human brain to aging. Ageing Research Reviews, 2023, 87, 101916.	10.9	4
1393	Genetic Risk for Alzheimer Disease and Plasma Tau Are Associated With Accelerated Parietal Cortex Thickness Change in Middle-Aged Adults. Neurology: Genetics, 2023, 9, .	1.9	1
1394	Common mouse models of tauopathy reflect early but not late human disease. Molecular Neurodegeneration, 2023, 18, .	10.8	11
1395	Multifactorial glial responses and their contributions to Alzheimer's disease continuum. Clinical and Experimental Neuroimmunology, 2023, 14, 82-91.	1.0	1
1396	White matter injury, cholesterol dysmetabolism, and APP/A β dysmetabolism interact to produce Alzheimer's disease (AD) neuropathology: A hypothesis and review. Frontiers in Aging Neuroscience, 0, 15, .	3.4	6
1397	Chronic basal forebrain activation improves spatial memory, boosts neurotrophin receptor expression, and lowers BACE1 and A β ₄₂ levels in the cerebral cortex in mice. Cerebral Cortex, 2023, 33, 7627-7641.	2.9	2
1398	Tau, A β -Amyloid, and Glucose Metabolism Following Service-Related Traumatic Brain Injury in Vietnam War Veterans: The Australian Imaging Biomarkers and Lifestyle Study of Aging-Veterans Study (AIBL-VETS). Journal of Neurotrauma, 2023, 40, 1086-1097.	3.4	2
1399	The past and present of therapeutic strategy for Alzheimer's diseases: potential for stem cell therapy. Experimental Animals, 2023, 72, 285-293.	1.1	2
1400	Entorhinal Cortex Functional Connectivity during Item Long-Term Memory and the Role of Sex. Brain Sciences, 2023, 13, 446.	2.3	0
1401	Thiophene-Based Ligands: Design, Synthesis and Their Utilization for Optical Assignment of Polymorphic Disease-Associated Protein Aggregates. ChemBioChem, 2023, 24, .	2.6	4
1402	Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology. Revue Neurologique, 2023, 179, 812-830.	1.5	6
1403	Aging impacts memory for perceptual, but not narrative, event details. Learning and Memory, 2023, 30, 48-54.	1.3	2
1404	An aging, pathology burden, and glial senescence build-up hypothesis for late onset Alzheimer's disease. Nature Communications, 2023, 14, .	12.8	26

#	ARTICLE	IF	CITATIONS
1406	CDK10, CDK11, FOXO1, and FOXO3 Gene Expression in Alzheimer's Disease Encephalic Samples. Cellular and Molecular Neurobiology, 0, , .	3.3	2
1408	<i>APOE</i> ϵ 4 associates with microglial activation independently of $A\beta$ plaques and tau tangles. Science Advances, 2023, 9, .	10.3	20
1409	Programmed ageing: decline of stem cell renewal, immunosenescence, and Alzheimer's disease. Biological Reviews, 2023, 98, 1424-1458.	10.4	12
1410	Entorhinal cortex epigenome-wide association study highlights four novel loci showing differential methylation in Alzheimer's disease. Alzheimer's Research and Therapy, 2023, 15, .	6.2	3
1412	Machine learning application for classification of Alzheimer's disease stages using 18F-flortaucipir positron emission tomography. BioMedical Engineering OnLine, 2023, 22, .	2.7	0
1413	Functional bioengineered tissue models of neurodegenerative diseases. Biomaterials, 2023, 298, 122143.	11.4	1
1414	Neuroimaging in Alzheimer's Disease for Early Diagnosis: A Comprehensive Review. Cureus, 2023, , .	0.5	2
1415	The Adult Neurogenesis Theory of Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 93, 1237-1276.	2.6	1
1416	Proteostatic modulation in brain aging without associated Alzheimer's disease-and age-related neuropathological changes. Aging, 2023, 15, 3295-3330.	3.1	1
1417	Depression Severity Is Different in Dysosmic Patients Who Have Experienced Traumatic Brain Injury Compared with Those Who Have Not. Neurology International, 2023, 15, 638-649.	2.8	1
1418	Visit-to-visit HbA1c variability, dementia, and hippocampal atrophy among adults without diabetes. Experimental Gerontology, 2023, 178, 112225.	2.8	2
1419	A Targeted Mass Spectrometry Approach to Identify Peripheral Changes in Metabolic Pathways of Patients with Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 9736.	4.1	2
1420	A cross-sectional study of explainable machine learning in Alzheimer's disease: diagnostic classification using MR radiomic features. Frontiers in Aging Neuroscience, 0, 15, .	3.4	3
1421	Perirhinal cortex is associated with fine-grained discrimination of conceptually confusable objects in Alzheimer's disease. Neurobiology of Aging, 2023, 130, 1-11.	3.1	1
1422	Biochemical analyses of tau and other neuronal markers in the submandibular gland and frontal cortex across stages of Alzheimer disease. Neuroscience Letters, 2023, 810, 137330.	2.1	2
1423	Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation. Neuron, 2023, 111, 2660-2674.e9.	8.1	4
1424	Characterization of an automated method to segment the human locus coeruleus. Human Brain Mapping, 2023, 44, 3913-3925.	3.6	3
1425	Quantitative Metabolic Magnetic Resonance Imaging: A Case for Bioscales in Medicine. , 2023, , 1239-1258.		0

#	ARTICLE	IF	CITATIONS
1426	CentTauR: Toward a universal scale and masks for standardizing tau imaging studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	2
1427	A data-driven study of Alzheimer's disease related amyloid and tau pathology progression. Brain, 2023, 146, 4935-4948.	7.6	1
1429	Analysis Of Raw 3D Images Of Stages Of Alzheimerâ€™s Disease Using Deep Learning. , 2023, , .		0
1430	Dynamic Multi-Task Graph Isomorphism Network for Classification of Alzheimerâ€™s Disease. Applied Sciences (Switzerland), 2023, 13, 8433.	2.5	0
1432	Alzheimerâ€™s disease and related tauopathies: disorders of disrupted neuronal identity. Trends in Neurosciences, 2023, 46, 797-813.	8.6	5
1433	Traits and Trammels of Tau Tracer Imaging. , 2023, , 85-107.		0
1434	Diagnostic and therapeutic targeting of pathological tau proteins in neurodegenerative disorders. FEBS Open Bio, 2024, 14, 165-180.	2.3	0
1435	APOE-Îµ4 and BIN1 increase risk of Alzheimerâ€™s disease pathology but not specifically of Lewy body pathology. Acta Neuropathologica Communications, 2023, 11, .	5.2	0
1436	APOEÎµ4 potentiates amyloid Î² effects on longitudinal tau pathology. Nature Aging, 2023, 3, 1210-1218.	11.6	0
1437	A robust and clinically applicable deep learning model for early detection of Alzheimer's. IET Image Processing, 2023, 17, 3959-3975.	2.5	2
1438	Modulation of associations between education years and cortical volume in Alzheimerâ€™s disease vulnerable brain regions by AÎ² deposition and APOE Îµ4 carrier status in cognitively normal older adults. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
1439	Insights to develop tau-directed therapeutics to protect the synaptic integrity for tauopathies. Bulletin of the Korean Chemical Society, 0, , .	1.9	0
1440	Retinal mid-peripheral capillary free zones are enlarged in cognitively unimpaired older adults at high risk for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0
1441	Deep Learning Enabled Classification of Cognitive Impairment Stages Using MRI Images. , 2023, , .		0
1442	Age-, sex-, and pathology-related variability in brain structure and cognition. Translational Psychiatry, 2023, 13, .	4.8	3
1443	Menopause age, reproductive span and hormone therapy duration predict the volume of medial temporal lobe brain structures in postmenopausal women. Psychoneuroendocrinology, 2023, 158, 106393.	2.7	1
1444	Tau truncation in the pathogenesis of Alzheimerâ€™s disease: a narrative review. Neural Regeneration Research, 2024, 19, 1221-1232.	3.0	2
1445	Serum transthyretin level and its relationship with cognitive function in community-dwelling older people: Cross sectional and longitudinal study. Archives of Gerontology and Geriatrics, 2023, 115, 105226.	3.0	0

#	ARTICLE	IF	CITATIONS
1447	Emerging role of antioxidants in Alzheimer's disease: Insight into physiological, pathological mechanisms and management. , 2024, 2, 100021.		0
1448	Neuropathological and sociodemographic factors associated with the cortical amyloid load in aging and Alzheimerâ€™s disease. GeroScience, 0, , .	4.6	0
1449	Multi-Target Neuroprotection of Thiazolidinediones on Alzheimerâ€™s Disease via Neuroinflammation and Ferroptosis. Journal of Alzheimer's Disease, 2023, 96, 927-945.	2.6	1
1451	Analysis of Costs for Imaging-Assisted Pharmaceutical Intervention in Alzheimerâ€™s Disease with Lecanemab: Snapshot of the First 3 Years. Journal of Alzheimer's Disease, 2023, 96, 1305-1315.	2.6	0
1453	Positive rate and quantification of amyloid pathology with [18F]florbetapir in the urban Chinese population. European Radiology, 0, , .	4.5	0
1454	Definition of a Threshold for the Plasma AÎ²42/AÎ²40 Ratio Measured by Single-Molecule Array to Predict the Amyloid Status of Individuals without Dementia. International Journal of Molecular Sciences, 2024, 25, 1173.	4.1	1
1455	PET imaging in Alzheimerâ€™s disease. Ukraïns'kij Å¾urnal Vãjs'kovoï Medicini, 2023, 4, 45-54.	0.6	0
1456	Cannabis use disorder contributes to cognitive dysfunction in Veterans with traumatic brain injury. Frontiers in Neurology, 0, 15, .	2.4	0
1457	Iatrogenic Alzheimerâ€™s disease in recipients of cadaveric pituitary-derived growth hormone. Nature Medicine, 2024, 30, 394-402.	30.7	3
1458	The role of microRNAs in understanding sex-based differences in Alzheimerâ€™s disease. Biology of Sex Differences, 2024, 15, .	4.1	0
1459	Path integration deficits are associated with phosphorylated tau accumulation in the entorhinal cortex. Brain Communications, 2023, 6, .	3.3	0
1460	Impaired 24-h activity patterns are associated with an increased risk of Alzheimerâ€™s disease, Parkinsonâ€™s disease, and cognitive decline. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
1461	Investigating the Potential Impact of Air Pollution on Alzheimerâ€™s Disease and the Utility of Multidimensional Imaging for Early Detection. ACS Omega, 2024, 9, 8615-8631.	3.5	0
1462	A single-domain antibody for the detection of pathological Tau protein in the early stages of oligomerization. Journal of Translational Medicine, 2024, 22, .	4.4	0
1465	Atrophy of hippocampal subfields and amygdala nuclei in subjects with mild cognitive impairment progressing to Alzheimer's disease. Heliyon, 2024, 10, e27429.	3.2	0
1467	Thiophene-Based Ligands for Specific Assignment of Distinct AÎ² Pathologies in Alzheimer's Disease. ACS Chemical Neuroscience, 2024, 15, 1581-1595.	3.5	0
1468	Iatrogenic cerebral amyloid angiopathy in older adults. European Journal of Neurology, 2024, 31, .	3.3	0
1469	Methods for Biochemical Isolation of Insoluble Tau in Rodent Models of Tauopathies. Methods in Molecular Biology, 2024, , 323-341.	0.9	0